Emerging trends from COVID-19 research registered in the Clinical Trials Registry - India

M. Vishnu Vardhana Rao†, Atul Juneja†, Mohua Maulik, Tulsi Adhikari†, Saurabh Sharma†, Jyotsna Gupta, Yashmin Panchal & Neha Yadav

Clinical Trials Registry-India, 'ICMR-National Institute of Medical Statistics, New Delhi, India

Received June 16, 2020

Since the beginning of the year, the deadly coronavirus pandemic, better known as coronavirus disease 2019 (COVID-19), brought the entire world to an unprecedented halt. In tandem with the global scenario, researchers in India are actively engaged in the conduct of clinical research to counter the pandemic. This review attempts to provide a comprehensive overview of the COVID-19 research in India including design aspects, through the clinical trials registered in the Clinical Trials Registry - India (CTRI) till June 5, 2020. One hundred and twenty two registered trials on COVID-19 were extracted from the CTRI database. These trials were categorized into modern medicine (n=42), traditional medicine (n=67) and miscellaneous (n=13). Of the 42 modern medicine trials, 28 were on repurposed drugs, used singly (n=24) or in combination (n=4). Of these 28 trials, 23 were to evaluate their therapeutic efficacy in different severities of the disease. There were nine registered trials on cell- and plasma-based therapies, two phytopharmaceutical trials and three vaccine trials. The traditional medicine trials category majorly comprised Ayurveda (n=45), followed by homeopathy (n=14) and others (n=8) from Yoga, Siddha and Unani. Among the traditional medicine category, 31 trials were prophylactic and 36 were therapeutic, mostly conducted on asymptomatic or mild-to-moderate COVID-19 patients. This review would showcase the research being conducted on COVID-19 in the country and highlight the research gaps to steer further studies.

Key words Ayurveda, Yoga and Naturopathy, Unani, Siddha, Homeopathy - clinical trials - CTRI-India - convalescent plasma therapy - COVID-19 - drug trials - registration - vaccine trials

The novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported from Wuhan, China, in December 2019. Since then, the disease has spread worldwide and as of June 5, 2020, there were 6,824,499 cases and 408,307 deaths globally. In the absence of any vaccine or definitive therapeutic strategy, medical scientists are working tirelessly to not only save lives but also search for effective treatment modalities against the deadly virus. Drug development is a costly and time-consuming process and is not feasible in the context of the immediate global challenge. Therefore, drug repurposing strategies are being considered to develop safe and effective treatment regimens against the disease. Currently, an array of drugs used for the other...
health conditions are being studied for the treatment of COVID-19 in several hundred clinical trials around the globe.

Globally, clinical trial registries may be considered the best source to review the ongoing clinical trial scenario as crucial details pertaining to proposed intervention, study type and design, sample size, and outcomes and phase of the trial are publicly available. The Clinical Trials Registry - India (CTRI), one of the primary registries of the World Health Organization’s International Clinical Trial Registry Platform (ICTRP), is one such database.

The CTRI, set up under the aegis of the Indian Council of Medical Research (ICMR), is managed by the ICMR-National Institute of Medical Statistics, New Delhi. The CTRI is a free online registry that prospectively registers clinical trials being conducted in India and also in countries which do not have a primary registry of their own. With the emergence of the pandemic in India, there has been a steady increase in the registration of clinical trials on COVID-19 in the CTRI. Here, we present a comprehensive overview of the COVID-19 trials registered in the CTRI (as on June 5, 2020). Overall, there were 23 single-armed trials, 68 randomized trials and six cluster randomized trials, while there were 17 non-randomized and eight other (unspecified study design) trials. Most of these trials were either Phase 2 (n=31) or Phase 2/3 (n=13) trials or Phase 3 (n=23) or Phase 3/4 (n=7) trials. Phase was not applicable for 34 trials, and there were only two Phase 1 and five Phase 1/2 trials (Tables II-IV). Of the remaining trials, four trials were marked as Phase 4 trials and two as post-marketing surveillance studies. There was a wide variation in sample size in the registered trials ranging from 6 to 50,000.

**Trial data extraction**

One hundred and twenty three registered COVID-19 trials were extracted from the CTRI database using the term %covid% in the different fields of the CTRI data set. These trials were manually screened and analyzed. One trial was excluded because COVID-19 was in the exclusion criteria in that trial. The remaining 122 trials were tabulated into three categories: modern medicine (including drug trials as well as phytopharmaceuticals, cell- and plasma-based therapies and biological products trials); traditional medicine covering Ayurveda, Yoga and Naturopathy, Unani, Siddha, Homeopathy (AYUSH) trials and miscellaneous trials.

**COVID-19 trial scenario in India**

Multiple therapeutic and preventive trials including those in the traditional systems of medicine are being conducted in India with the common global objective of demonstrating efficacy as well as safety for all in need. Of the 122 clinical trials on COVID-19 registered in the CTRI, 42 were on the modern system of medicine, 67 on the traditional system of medicine and 13 miscellaneous (Table I). Overall, there were 23 single-armed trials, 68 randomized trials and six cluster randomized trials, while there were 17 non-randomized and eight other (unspecified study design) trials. Most of these trials were either Phase 2 (n=31) or Phase 2/3 (n=13) trials or Phase 3 (n=23) or Phase 3/4 (n=7) trials. Phase was not applicable for 34 trials, and there were only two Phase 1 and five Phase 1/2 trials (Tables II-IV). Of the remaining trials, four trials were marked as Phase 4 trials and two as post-marketing surveillance studies. There was a wide variation in sample size in the registered trials ranging from 6 to 50,000.

**Modern medicine**

Trials registered in this category (n=42) are subdivided into drug trials (n=28), of which 24 trials are on individual drugs which primarily evaluate their therapeutic efficacy (n=19) as do all of the four combination of drug trials (such as the global Solidarity trial). These trials are being conducted in patients with varying severity of COVID-19 ranging from mild to moderate to severe. The severity of COVID-19 has not been specified in seven of these drug trials (Table I). Others include trials on phytopharmaceuticals (n=2) cell- and plasma-based therapies (n=9) and biological products (n=3). Only one of these is a prophylactic trial on healthy volunteers and all cell- and plasma-based therapy trials are on either moderate/moderate to severe or severe (n=5) COVID-19 patients. While the key features of these registered trials are presented in Table II, these are briefly discussed below.

**Drug trials**

**Antivirals**

**Solidarity trial:** The Solidarity trial is an international clinical trial initiated by the WHO to help find an effective treatment for COVID-19. The trial compares four treatment options remdesivir; lopinavir/ritonavir; lopinavir/ritonavir with interferon beta-1a and chloroquine or hydroxychloroquine (HCQ) against standard of care, to assess their relative effectiveness against COVID-19. The Solidarity trial has been planned as an open-labelled, randomized, parallel-group, multiple-arm trial with a total sample size of 7000 participants, of whom 1500 participants are
| Intervention                  | Number | Type of trial          | Participant health condition                                      |
|------------------------------|--------|------------------------|------------------------------------------------------------------|
| **Modern medicine (n=42)**   |        |                        |                                                                  |
| Individual drugs             | 24     | Therapeutic efficacy=19 | Healthy volunteers at high risk - 4                              |
|                              |        |                         | Healthy volunteers at moderate/high risk - 1                     |
|                              |        | Prophylactic efficacy=5 | Mild COVID-19 - 5                                               |
|                              |        |                        | Mild-to-moderate COVID-19 - 1                                    |
|                              |        |                        | Moderate COVID-19 - 1                                            |
|                              |        |                        | Moderate-to-severe COVID-19 - 2                                  |
|                              |        |                        | Severe COVID-19 - 4                                             |
|                              |        |                        | Severity not specified - 6                                       |
| Combination drugs            | 4      | Therapeutic efficacy=4  | Moderate COVID-19 - 1                                           |
|                              |        |                        | Mild, moderate, severe COVID-19 - 1                              |
|                              |        |                        | Non-severe and severe COVID-19 - 1                              |
|                              |        |                        | Severity not specified - 1                                       |
| **Phytopharmaceutical (n=2)**|        |                        |                                                                  |
|                               | 2      | Therapeutic efficacy=2  | Asymptomatic/mild COVID-19 - 1                                   |
|                               |        |                        | Moderate COVID-19 - 1                                            |
| **Cell- and plasma-based therapies (n=9)** |        |                        |                                                                  |
|                               | 9      | Therapeutic efficacy=9  | Moderate COVID-19 - 1                                           |
|                               |        |                        | Moderate-to-severe COVID-19 - 1                                  |
|                               |        |                        | Severe COVID-19 - 5                                             |
|                               |        |                        | Severity not specified - 2                                       |
| **Biological products (n=3)** |        |                        |                                                                  |
|                               | 3      | Therapeutic efficacy=2  | Healthy volunteers at high risk - 1                              |
|                               |        | Prophylactic efficacy=1 | Moderate-to-severe COVID-19 - 1                                  |
|                               |        |                        | Severe COVID-19 - 1                                             |
| **Traditional medicine (n=67)**|        |                        |                                                                  |
|                               |        |                        |                                                                  |
| **Ayurveda (n=45)**          |        |                        |                                                                  |
| Classical individual agents  | 11     | Therapeutic efficacy=1  | Healthy volunteers at high risk - 1                              |
|                              |        | Prophylactic efficacy=10| Healthy volunteers in the community - 9                          |
|                              |        |                        | Asymptomatic/mild symptoms - 1                                   |
| Classical combination         | 10     | Therapeutic efficacy=4  | Healthy volunteers at high risk - 1                              |
| preparations                  |        | Prophylactic efficacy=6 | Healthy volunteers in the community - 5                          |
|                              |        |                        | Asymptomatic/mild symptoms - 3                                   |
|                              |        |                        | Mild-to-moderate COVID-19 - 1                                    |
| Patented products             | 24     | Therapeutic efficacy=18 | Healthy volunteers at high risk - 5                              |
|                              |        | Prophylactic efficacy=6 | Healthy volunteers in the community - 1                          |
|                              |        |                        | Asymptomatic/mild symptoms - 3                                   |
|                              |        |                        | Asymptomatic/mild/moderate symptoms - 2                          |
|                              |        |                        | Mild symptoms - 4                                                |
|                              |        |                        | Mild-to-moderate COVID-19 - 6                                    |
|                              |        |                        | Moderate COVID-19 - 1                                            |
|                              |        |                        | Moderate-to-severe COVID-19 - 1                                  |
| Yoga (n=3)                   | 3      | Therapeutic efficacy=2  | Healthy volunteers at high risk - 1                              |
|                              |        | Stress management=1     | Asymptomatic/mild symptoms - 1                                   |
|                              |        |                        | Asymptomatic/uncomplicated illness/mild pneumonia - 1            

*Contd...*
to be enrolled from India from 24 sites. The trial is being conducted in India with the support of ICMR.

In addition, a single-centre trial is also underway to assess the safety and efficacy of antiviral combination therapy such as lopinavir–ritonavir combination and HCQ with ribavirin in severe COVID-19-infected patients (CTRI/2020/06/025575).

Favipiravir: A nucleoside precursor, favipiravir, inhibits the influenza virus as well as a number of other RNA viruses\(^6\). In keeping with global trends, a randomized, open-label, multicentre study to evaluate the efficacy and safety of favipiravir in addition to standard supportive care in patients with mild-to-moderate COVID-19 is currently underway at 12 sites across India (CTRI/2020/05/025114).

### Antimalarials

During this pandemic time, chloroquine and HCQ have generated much interest in the global community as potential therapeutic agents against COVID-19\(^7\). An open-label non-randomized trial showed that HCQ - azithromycin was associated with viral load reduction in COVID-19 patients\(^8\).

Chloroquine: Two open-labelled, randomized controlled trials are being conducted to determine the efficacy of chloroquine in COVID-19 patients who present with severe acute respiratory illness (CTRI/2020/04/024479, CTRI/2020/04/024729).

Hydroxychloroquine (HCQ): In India, the ICMR has proposed a prophylactic dosing schedule of HCQ for healthcare workers\(^9\). In this regard, a principal investigator (PI)-initiated trial on 500 participants is currently underway wherein the recommended prophylactic dosing regimen is being compared with an alternative dosing pattern for the prevention of new infection and adverse outcomes in those at high risk of infection (CTRI/2020/03/024402). A double-blind, Phase 3 clinical trial, sponsored by the Armed Forces Medical Services, aims to evaluate the efficacy of two different doses of HCQ and also to compare the efficacy of HCQ with or without azithromycin in mild, moderate and severe COVID-19-infected patients. This trial is being conducted at six sites across the country with 300 participants.

In view of the large-scale use of HCQ in India, a study to document the pharmacokinetics of HCQ in the Indian population has also been registered

### Intervention

| Intervention  | Number | Type of trial | Participant health condition |
|---------------|--------|---------------|------------------------------|
| **Unani (n=2)**

Unani

| Number | Therapeutic efficacy=2 | Prophylactic efficacy=1 |
|--------|-------------------------|--------------------------|
| 2      | Healthy volunteers at risk - 2 |

Siddha (n=3)

| Number | Therapeutic efficacy=2 | Prophylactic efficacy=1 |
|--------|-------------------------|--------------------------|
| 3      | Healthy volunteers in community and healthcare workers - 1 |
|        | Asymptomatic - 1 |
|        | Asymptomatic/mild/moderate symptoms - 1 |

**Homeopathy (n=14)**

| Number | Therapeutic efficacy=8 | Prophylactic efficacy=6 |
|--------|-------------------------|--------------------------|
| 14     | Healthy volunteers in community - 3 |
|        | Healthy volunteers at high risk - 3 |
|        | Asymptomatic - 1 |
|        | Asymptomatic/mild symptoms - 1 |
|        | Mild - 4 |
|        | Moderate - 1 |
|        | Mild/moderate/severe symptoms - 1 |

**Miscellaneous (n=13)**

| Number | Therapeutic efficacy=2 | Prophylactic efficacy=1 | Process-of-care changes=9 | Diagnostic=1 |
|--------|-------------------------|--------------------------|---------------------------|--------------|
| 13     | Healthy volunteers - 4 |
|        | Severe COVID-19 - 1 |
|        | Severity not specified - 4 |
|        | Other (non-COVID-19) - 4 |

*Registered trials as on June 5, 2020; Two Ayurveda classical combination trials included yoga and one yoga trial included Ayurveda interventions. In addition, one Ayurveda trial was in combination with homeopathy and one miscellaneous trial with combination of modern medicine, Ayurveda and homeopathy.*

[Downloaded free from http://www.ijmr.org.in on Wednesday, August 11, 2021, IP: 14.139.60.52]
**Table II.** Details of modern medicine trials (n=42) on COVID-19 registered in the Clinical Trials Registry - India*

| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|----------------|---------------------------|----------------|
| **Drug trials (n=28)** | | | | | | | | | |
| **Antivirals** | | | | | | | | | |
| 1 | CTRI/2020/04/024773 | Arm 1: Remdesivir and standard treatment Arm 2: Chloroquine or HCQ and standard treatment Arm 3: Lopinavir with ritonavir Arm 4: Lopinavir with ritonavir plus interferon and standard treatment Arm 5: Standard treatment | Randomized, parallel-group, multiple-arm trial | Open label | Phase 3 | 1500 | All-cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study | WHO and ICMR, New Delhi DCGI approval: Yes | RJ (2 sites), MP (2 sites), DL, TN (5 sites), MH (7 sites), GJ (4 sites), TS, GJ, AP |
| 2 | CTRI/2020/06/025575 | Arm 1: HCQ, ribavirin, standard treatment (NS) Arm 2: HCQ, ribavirin, standard treatment (S) Arm 3: Lopinavir, ritonavir, ribavirin, standard treatment (S) Arm 4: Standard treatment (NS) Arm 5: Standard treatment | Randomized, parallel-group, multiple-arm trial | Open label | Phase 3/ Phase 4 | 175 | 1. Time to clinical recovery 2. Time to 2019-nCoV RT-PCR negativity in upper respiratory tract specimen | AIIMS, Rishikesh DCGI approval: N/A | UK |
| 3 | CTRI/2020/05/025114 | Arm 1: Favipiravir Arm 2: Standard treatment | Randomized, parallel-group trial | Open label | Phase 3 | 150 | Time until cessation of oral shedding of SARS-CoV-2 virus (time frame: up to 28 days) (time in days from randomization to a negative SARS-CoV-2 RT-PCR result of both oropharyngeal swab and nasopharyngeal swab) | Glenmark Pharmaceuticals Ltd, Mumbai DCGI approval: Yes | CG, MH (7 sites), GJ (3 sites), DL |
| **Antimalarials** | | | | | | | | | |
| 4 | CTRI/2020/04/024479 | Arm 1: Chloroquine phosphate Arm 2: Standard treatment | Randomized, parallel-group trial | Open label | N/A | 32 | Number of days of hospitalization | Command Hospital Airforce, Bengaluru DCGI approval: N/A | KA |

Contd...
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|----------------|--------------------------|----------------|
| 5             | CTRI/2020/04/024729 | Arm 1: Topical chloroquine and standard treatment  
Arm 2: Standard treatment | Other | Open label | Phase 2 | 60 | 1. The Ct values on days 0, 3, 7, 10 shall be plotted on a graph for all patients.  
2. The rate of decline for each patient shall be calculated. The time to cure (COVID-19 RT PCR -ve) shall be determined.  
3. The two groups shall be compared for (i) rate of decline of Ct values; (ii) time to cure; (iii) rate of cure or alternate outcome | AIIMS New Delhi  
DCGI approval: N/A | HR |
| 6             | CTRI/2020/03/024402 | Arm 1: HCQ  
Arm 2: HCQ (ICMR regimen) | Randomized, parallel-group, active controlled trial | Open label | Phase 3 | 500 | Infected non-infected | PI initiated, Aster Malabar Institute of Medical Sciences, Kozhikode  
DCGI approval: N/A | KL |
| 7             | CTRI/2020/05/025022 | Arm 1: HCQ  
Arm 2: Standard treatment | Other | Open label | Phase 2 | 166 | Progression to moderate-to-severe disease | AIIMS, New Delhi  
DCGI approval: N/A | DL |
| 8             | CTRI/2020/05/025067 | Arm 1: HCQ along with standard treatment  
Arm 2: Standard treatment | Randomized, parallel-group trial | Open label | N/A | 6950 | Laboratory-confirmed symptomatic COVID-19 cases | George Institute for Global Health India, New Delhi  
DCGI approval: N/A | TN, KA, DL |
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|---------------------|--------------|----------|-------|-------------|----------------|--------------------------|----------------|
| 9             | CTRI/2020/04/024904 | Arm 1: HCQ  
Arm 2: HCQ (high dose)  
Arm 3: HCQ and Azithromycin | Randomized, parallel group trial | Participant and outcome assessor blinded | Phase 3 | 300 | 1. Death  
2. Hospitalized on invasive mechanical ventilation or extracorporeal mechanical ventilation  
3. Hospitalized on non-invasive ventilation or high-flow nasal cannula oxygen therapy  
4. Hospitalized on supplemental oxygen  
5. Hospitalized not on supplemental oxygen  
6. Not hospitalized with limitation of activity (due to continued symptoms)  
7. Not hospitalized without limitation in activity (no symptoms) | Armed Forces Medical Services, New Delhi  
DCGI approval: N/A | UP (4 sites), DL, GJ |
| 10            | CTRI/2020/05/025242 | Arm 1: HCQ | Other | N/A | N/A | 400 | Pharmacokinetics of HCQ | ICMR, New Delhi  
DCGI approval: N/A | MH |

**Immunomodulators**

| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|---------------------|--------------|----------|-------|-------------|----------------|--------------------------|----------------|
| 11            | CTRI/2020/04/024948 | Arm 1: Ciclesonide  
Arm 2: HCQ  
Arm 3: Ivermectin  
Arm 4: Standard treatment | Randomized, parallel-group trial | N/A | Phase 2 | 120 | Proportion of patients having virologic cure on day 6 in each of the groups | Lady Hardinge Medical College, New Delhi  
DCGI approval: N/A | DL |
| 12            | CTRI/2020/04/024806 | Arm 1: Imatinib  
Arm 2: Standard treatment | Randomized, parallel-group trial | Open label | Phase 2 | 100 | 1. Proportion of patients with negative viral titre on day 7  
2. Proportion of patients with negative viral titre on day 14 | AIIMS New Delhi  
DCGI approval: N/A | DL |
| Serial number | CTRI number   | Intervention details                                      | Study design                                                                 | Blinding      | Phase | Sample size | Primary outcome                                                                 | Sponsor and regulatory status                                                                 | States and UTs                      |
|---------------|---------------|-----------------------------------------------------------|-----------------------------------------------------------------------------|---------------|-------|-------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------|
| 13            | CTRI/2020/05/024959 | Arm 1: Itolizumab, Arm 2: Standard treatment          | Randomized, parallel-group, active controlled trial                         | Open label    | Phase 2 | 30          | One-month mortality rate                                                       | Biocon Biologics India Limited, Bengaluru                                                | DL (3 sites), MH (3 sites), KA       |
| 14            | CTRI/2020/05/025369 | Arm 1: Tocilizumab and standard treatment, Arm 2: Standard treatment | Randomized, parallel-group, active controlled trial                         | Open label    | Phase 3 | 180         | Proportion showing progressive COVID-19 disease from moderate to severe, or from severe disease to death | Medanta Institute of Education and Research, Gurgaon                                         | TS, TN, MH (3 sites), HR (4 sites) DL, UP (2 sites) |
| 15            | CTRI/2020/04/024846 | Arm 1: *Mycobacterium* w and standard treatment, Arm 2: Placebo and standard treatment | Randomized, parallel-group, placebo-controlled trial                       | Participant, N/A investigator and outcome assessor blinded | N/A     | 40          | Improvement in organ dysfunction (or occurrence of new organ dysfunction) based on change in SOFA score and ordinal scale | Cadila Pharmaceuticals Limited, Ahmedabad                                               | CG, MP, DL, CH                      |
| 16            | CTRI/2020/05/025271 | Arm 1: *Mycobacterium* w and standard treatment, Arm 2: Placebo and standard treatment | Randomized, parallel-group, placebo-controlled trial                       | Participant, investigator and outcome assessor blinded                   | Phase 3  | 480         | Number of patients with increased disease severity                              | Cadila Pharmaceuticals Limited, Ahmedabad                                               | DL, MP, CH                          |
| 17            | CTRI/2020/05/025277 | Arm 1: *Mycobacterium* w, Arm 2: Placebo                  | Randomized, parallel-group, placebo-controlled trial                       | Participant, investigator and outcome assessor blinded                   | Phase 3  | 4000        | Number of individuals acquiring COVID-19 infection                               | Cadila Pharmaceuticals Limited, Ahmedabad                                               | MP, CG, DL, CH                      |
| Serial number | CTRI number | Intervention details | Sample and primary outcome size | Study design | Blinding | Phase | Sponsor and regulatory status |
|---------------|-------------|----------------------|-------------------------------|--------------|----------|------|-------------------------------|
| 18            | CTRI/2020/05/025350 | Arm 1: Mycobacterium w, (heat killed) | 50 | Clinical improvement, as defined by live discharge from the hospital, a decrease of at least two points from baseline on a modified ordinal scale. | N/A | Open label | MP DCGI approval: UK |
| 19            | CTRI/2020/06/025613 | Arm 1: Melatonin, Arm 2: Placebo | 200 | SARS-CoV-2 infection rate | Participant and investigator blinded | Randomized, parallel-group, placebo-controlled | DCGI approval: N/A |
| 20            | CTRI/2020/04/024858 | Arm 1: Ivermectin and standard treatment, Arm 2: Standard treatment | 50 | To confirm the antiviral effectiveness of ivermectin on COVID-19 then to explore its potential use in the combating COVID-19 pandemic | DCGI approval: N/A |
| 21            | CTRI/2020/05/025068 | Arm 1: Ivermectin, Arm 2: Standard treatment | 50 | Reduction in the viral load in patients with haematological illnesses who are admitted with COVID-19 infection | DCGI approval: N/A |
| 22            | CTRI/2020/05/025224 | Arm 1: Ivermectin, and standard treatment, Arm 2: Standard treatment | 50 | Effect of ivermectin on eradication of virus. Test for virus at 1, 3 and 5 days from beginning of trial drug started for the patient in the hospital | DCGI approval: N/A |
| Serial number | CTRI number       | Intervention details                                                                 | Study design                      | Blinding       | Phase | Sample size | Primary outcome                                                                                                                                  | Sponsor and regulatory status                                                                 | States and UTs |
|--------------|-------------------|--------------------------------------------------------------------------------------|-----------------------------------|----------------|-------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------|
| 23           | CTRI/2020/05/025333 | Arm 1: Ivermectin  
Arm 2: No intervention                                            | Randomized, parallel-group trial | Open label | Phase 2 | 2000        | 1. Resolution of signs and symptoms of COVID-19  
2. Negative RT-PCR done 48 h after ivermectin dose  
3. Change/reduction in Ct value as reported in RT-PCR for SARS-CoV-2 virus assay | R D Gardi Medical College, Ujjain  
DCGI approval: N/A                                                                 | MP                          |
| 24           | CTRI/2020/04/024949 | Arm 1: Niclosamide  
Arm 2: Standard treatment                                           | Randomized, parallel-group trial | N/A           | Phase 2 | 48          | Proportion of patients having virologic cure on day 6                                      | Lady Hardinge Medical College, New Delhi  
DCGI approval: N/A                                                                                           | DL                          |
|              |                   |                                                                                     |                                   |                |       |             |                                                                                                                                                      |                                                                                                                                                   |               |
|              |                   |                                                                                     |                                   |                |       |             |                                                                                                                                                      | Antihypertensive                                                                                         |               |
| 25           | CTRI/2020/05/025319 | Arm 1: Losartan  
Arm 2: Placebo                                                      | Randomized, parallel-group, placebo-controlled trial | Participant and investigator blinded | Phase 3 | 186         | Percentage of patients with treatment failure:  
(i) fall in 1 score in Respiratory SOFA score;  
(ii) new requirement of respiratory assist devices (HFNC, NIV);  
(iii) new requirement of mechanical ventilation;  
(iv) mortality | SGPGI, Lucknow  
DCGI approval: N/A                                                                                           | UP                          |
|              |                   |                                                                                     |                                   |                |       |             |                                                                                                                                                      |                                                                                                                                                    |               |
| 26           | CTRI/2020/05/025336 | Arm 1: Resveratrol-copper and standard treatment  
Arm 2: Sodium-copper-chlorophyllin and standard treatment  
Arm 3: Standard treatment | Randomized, parallel-group, multiple-arm trial | Open label | Phase 3 | 300         | Proportion of patients who suffer clinical deterioration OR viral persistence at day 10 from the date of randomization (excluding the date of randomization) | Tata Memorial Centre, Mumbai  
DCGI approval: N/A                                                                                           | MH                          |
| Serial number | CTRI number          | Intervention details                                                                 | Study design                           | Blinding   | Phase   | Sample size | Primary outcome                                                                 | Sponsor and regulatory status                       | States and UTs                      |
|--------------|----------------------|---------------------------------------------------------------------------------------|----------------------------------------|------------|---------|-------------|---------------------------------------------------------------------------------|---------------------------------------------|-----------------------------------|
| 27           | CTRI/2020/05/025337  | Arm 1: Resveratrol-copper tablets, and standard treatment<br>Arm 2: Sodium-copper-chlorophyllin and standard treatment<br>Arm 3: Standard treatment | Randomized, parallel-group, multiple-arm trial | Open label | Phase 2 | 200         | Time to clinical improvement, defined as a 2-point improvement on a 7-point ordinal scale | Tata Memorial Centre, Mumbai DCGI approval: N/A | MH                               |
| 28           | CTRI/2020/06/025664  | Arm 1: 2-deoxy-D-glucose and standard treatment<br>Arm 2: Standard treatment          | Randomized, parallel-group, active controlled trial | Open label | Phase 2 | 40          | Time to clinical improvement                                                   | Dr Reddys Laboratories Limited, Hyderabad and INMAS, DRDO, Delhi DCGI approval: Yes | DL (2 sites), KA, TN, UP (2 sites), MH (4 sites), AP, GJ |
|              |                      | Antineoplastic                                                                        |                                        |            |         |             |                                                                                 |                                             |                                   |
| 29           | CTRI/2020/05/025397  | Arm 1: Purified AQCH and standard treatment<br>Arm 2: Standard treatment            | Randomized, parallel-group trial       | Open label | Phase 2 | 210         | Proportion of patients showing clinical improvement. Clinical improvement defined as patient meeting discharge criteria OR a 2-point improvement (from time of enrolment) in disease severity rating on the 7-point ordinal scale | Sun Pharmaceutical Industries Limited, Goregaon, Mumbai DCGI approval: Yes | CG, MH (6 sites), MR, TS, UP, HR, JK, DL, TN |
| 30           | CTRI/2020/05/025167  | Arm 1: Thymoquinone and standard treatment<br>Arm 2: Standard treatment            | Non-randomized active controlled trial | Open label | Phase 2 | 100         | Characterize virologic and clinical response                                    | Intas Pharmaceuticals Ltd, Ahmedabad DCGI approval: N/A | GJ (3 sites)                      |

Contd...
| Serial number | CTRI number       | Intervention details                                                                 | Study design                        | Blinding | Phase | Sample size | Primary outcome                                                                 | Sponsor and regulatory status     | States and UTs                      |
|---------------|-------------------|--------------------------------------------------------------------------------------|-------------------------------------|----------|-------|-------------|---------------------------------------------------------------------------------|-----------------------------------|-------------------------------------|
| 31            | CTRI/2020/04/024775 | Arm 1: Convalescent plasma<br>AArm 2: Standard treatment<br><br>PLACID trial    | Randomized, parallel-group, active controlled trial<br>Arm 1: Convalescent plasma<br>AArm 2: Standard treatment<br>Randomized, parallel-group, active controlled trial | N/A  | Phase 2 | 452          | Composite measure of the avoidance of:<br>(i) progression to severe ARDS (P/F ratio 100)<br>(ii) all-cause mortality at 28 days     | ICMR, New Delhi<br>DCGI approval: Yes | MH (7 sites), BR, MP (3 sites),<br>TS (2 sites) GJ (6 sites), KA (4 sites),<br>PY, UP (4 sites),<br>DL, TN (5 sites),<br>HR, CH, PB, RJ (2 sites) |
| 32            | CTRI/2020/04/024706 | Arm 1: Convalescent plasma and standard treatment<br>AArm 2: Random donor plasma and standard treatment | Randomized, parallel-group, active controlled trial | Open label | Phase 2 | 40          | Proportion of patients remaining free of mechanical ventilation in both groups | Institute of Liver and Biliary Sciences, New Delhi<br>DCGI approval: Yes | DL (2 sites)                      |
| 33            | CTRI/2020/04/024915 | Arm 1: Convalescent plasma<br>AArm 2: Standard treatment<br>Random donor plasma and standard treatment | Randomized, parallel-group trial | Open label | Phase 2 | 100         | The primary outcome was a composite measure of the avoidance of:<br>(i) progression to severe ARDS (P/F ratio 100)<br>(ii) all-cause mortality at 28 days     | Max Super Speciality Hospital, New Delhi<br>DCGI approval: Yes | DL                                |
| 34            | CTRI/2020/04/024804 | Arm 1: Convalescent plasma along with standard treatment<br>AArm 2: Standard treatment | Non-randomized, active controlled trial | N/A  | Phase 1/2 | 24          | Safety, efficacy, side effects measured by chest radiograph. Improvement of clinical symptoms including duration of fever, respiratory distress, pneumonia, cough, sneezing, and diarrhoea within three days of the convalescent plasma transfusion | International Stemcell Services Ltd, Bengaluru<br>DCGI approval: Yes | KA (2 sites)                      |

Contd...
| Serial number | CTRI number         | Intervention details                                      | Study design                  | Blinding   | Phase | Sample size | Primary outcome                                                                                                    | Sponsor and regulatory status                                      | States and UTs |
|--------------|-------------------|----------------------------------------------------------|-------------------------------|------------|-------|-------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|----------------|
| 35           | CTRI/2020/05/025299 | Arm 1: Convalescent plasma Arm 2: Standard treatment | Randomized, parallel-group trial | Open label | Phase 2 | 20          | Avoidance of progression to severe ARDS                                                                       | Wockhardt Ltd, Mumbai DCGI approval: Yes                              | MH             |
| 36           | CTRI/2020/05/025346 | Arm 1: Convalescent plasma and standard treatment Arm 2: Standard treatment | Randomized, parallel-group trial | N/A        | N/A    | 90          | Progression to severe ARDS (P/F ratio 100) and all-cause mortality at one month                               | Government of Tamil Nadu DCGI approval: Yes                           | TN             |
| 37           | CTRI/2020/05/025328 | Arm 1: Convalescent plasma Arm 2: Standard treatment | Randomized, parallel-group active controlled trial | N/A        | Phase 2 | 100         | Composite measure of the (i) all-cause mortality at 28 days; (ii) improvement of SOFA score post transfusion | Apollo Hospitals Enterprise Limited, New Delhi DCGI approval: Yes      | WB, TS, MH, TN, DL |
| 38           | CTRI/2020/05/025209 | Arm 1: Convalescent plasma Arm 2: Standard treatment | Randomized, parallel-group trial | Open label | Phase 2 | 80          | 1. All-cause mortality 2. To identify the immune correlates for response to plasma therapy                   | CSIR, New Delhi WB DCGI approval: Yes                                 |                  |
| 39           | CTRI/2020/05/025432 | Arm 1: Cytokine cocktail therapy | Single-arm Trial | Open label | Phase 1 | 6           | Safety of cytokine cocktail therapy                                                                             | International Stemcell Services Ltd, Bengaluru DCGI approval: Yes    | KA             |
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|----------------|-----------------------------|----------------|
| 40            | CTRI/2020/04/024749 | Arm 1: Recombinant BCG vaccine - VPM1002  
Arm 2: Placebo | Randomized, parallel-group, placebo controlled trial | Participant, investigator, outcome assessor and date-entry operator blinded | Phase 3 | 5946 | 1. Number of individuals with laboratory-confirmed COVID-19 infection  
2. Number of individuals with laboratory-confirmed COVID-19 infection among other high risk individuals  
3. Number of laboratory-confirmed COVID-19 infection with severe, critical or life-threatening disease as assessed by investigator among HCWs  
4. Number of laboratory-confirmed COVID-19 infection with severe, critical or life-threatening disease as assessed by investigator among other high-risk individuals | Serum Institute of India Pvt Ltd, Pune  
DCGI approval: Yes | OR, CG, MH  
(17 sites),  
DL (4 sites),  
GA, KL, AP, UP,  
WB, CH, HR, RJ,  
GJ, TN, KA  
(2 sites) |
| 41            | CTRI/2020/04/024833 | Arm 1: BCG-Denmark (Green Signal)  
Arm 2: Placebo | Randomized, parallel-group, placebo controlled trial | Participant, investigator, outcome assessor and date-entry operator blinded | N/A | 1826 | Proportion of HCW with symptomatic COVID-19 disease | PI initiated, JIPMER, Puducherry  
DCGI approval: N/A | PY |

Contd...
| Serial number | CTRI number            | Intervention details             | Study design               | Blinding              | Phase | Sample size | Primary outcome                                                                 | Sponsor and regulatory status                  | States and UTs |
|---------------|------------------------|----------------------------------|----------------------------|-----------------------|-------|-------------|--------------------------------------------------------------------------------|-----------------------------------------------|----------------|
| 42            | CTRI/2020/05/025013    | Arm 1: BCG Arm 2: Saline plus standard treatment | Non-randomized, active controlled trial | Participant blinded  | Phase 2 | 60          | 1. Total duration of hospitalization with COVID-19 symptoms  
2. Decrease in viral titre  
3. Duration of COVID-19 symptoms | Medical Education and Drugs Department, Mumbai  
DCGI approval: Yes | MH |

*Registered trials as on June 5, 2020. Combination therapy trials are mentioned in only one category to avoid duplication. Table data are as per information provided by trialist. The keyword 'Standard treatment' has been used for uniformity and includes the following category as mentioned by the trialist i.e., standard of care, standard care of treatment and supportive management, standard treatment protocol, local-level standard treatment, best supportive care and treatment guidelines as per MoHFW. COVID-19, coronavirus disease 2019; AIIMS, All India Institute of Medical Sciences; ICMR, Indian Council of Medical Research, INMAS, Institute of Nuclear Medicine and Allied Sciences; DRDO, Defence Research and Development Organisation; HCQ, Hydroxychloroquine; R D Gardi Medical College, Ruxmaniben Deepchand Gardi Medical College; SGPGI, Sanjay Gandhi Postgraduate Institute of Medical Sciences; CSIR, Council of Scientific and Industrial Research; WHO, World Health Organization. PI, Principal investigator; N/A, not applicable; AQCH, aqueous extract of Cocculus hirsutus; CTRI, Clinical Trials Registry - India; HCQ, healthcare workers; RT-PCR, reverse transcription-polymerase chain reaction; SOFA, sequential organ failure assessment; NS, non-severe; S, severe; Ct, cycle threshold. States and Union Territories (UTs): AP: Andhra Pradesh; AR: Arunachal Pradesh; AS: Assam; BR: Bihar; CG: Chhattisgarh; GA: Goa; GJ: Gujarat; HR: Haryana; HP: Himachal Pradesh; JK: Jammu and Kashmir; JH: Jharkhand; KA: Karnataka; KL: Kerala; MP: Madhya Pradesh; MH: Maharashtra; MN: Manipur; ML: Meghalaya; MZ: Mizoram; N: Nagaland; OR: Odisha; PB: Punjab; RJ: Rajasthan; SK: Sikkim; TN: Tamil Nadu; TR: Tripura; UK: Uttarakhand; UP: Uttar Pradesh; WB: West Bengal; TS: Telangana; AN: Andaman and Nicobar Islands; CH: Chandigarh; DH: Dadra and Nagar Haveli; DD: Daman and Diu; DL: Delhi; LD: Lakshadweep; PY: Puducherry.
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|---------------------|--------------|----------|-------|-------------|----------------|--------------------------|----------------|
| 1             | CTRI/2020/06/025525 | Arm 1: *Guduchi Ghana Vati* | Other | Open label | N/A  | 20000       | Incidence rate of COVID-19 infection | IPGTRA, Jamnagar DCGI approval: N/A | GJ (5 sites) |
|               |             | Arm 2: Nil          |              |          |       |             |                |                          |                |
| 2             | CTRI/2020/05/025488 | Arm 1: *Guduchi Ghana Vati* | Randomized, parallel-group trial | Open label | Phase 2/3 | 12000       | Comparative assessment of incidence of COVID-19 | NIA, Jaipur DCGI approval: N/A | RJ |
|               |             | Arm 2: Nil          |              |          |       |             |                |                          |                |
| 3             | CTRI/2020/05/025485 | Arm 1: *Guduchi Ghana Vati* | Non-randomized, active controlled trial | Open label | Phase 2/3 | 5000        | Comparative assessment of occurrence of COVID-19 infection | NIMH (CCRAS), Hyderabad DCGI approval: N/A | TS |
|               |             | Arm 2: Standard prophylactic care |              |          |       |             |                |                          |                |
| 4             | CTRI/2020/05/025385 | Arm 1: *Guduchi Ghana Vati* | Non-randomized, multiple-arm trial | N/A | N/A | 40000       | Comparative assessment of occurrence of COVID-19 infection | CCRAS, New Delhi DCGI approval: N/A | WB, PB, TN, KL (2 sites), MH (2 sites), NL, MP, RJ (2 sites), UP, AS, BR (2 sites), KA, HP, GJ (2 sites), AP |
|               |             | Arm 2: Standard prophylactic care |              |          |       |             |                |                          |                |
| 5             | CTRI/2020/05/025370 | Arm 1: *Guduchi Ghana Vati* | Single-arm trial | Open label | N/A | 40          | Clinical cure rate: Time to get a negative status of COVID-19 | Ayurved University, Jodhpur DCGI approval: N/A | RJ (2 sites) |
|               |             |                      |              |          |       |             |                |                          |                |
| 6             | CTRI/2020/05/025213 | Arm 1: *Guduchi Ghana Vati* | Single-arm trial | N/A | N/A | 1500        | Incidence of COVID-19-positive cases as confirmed by RT-PCR | CCRAS, New Delhi DCGI approval: N/A | HP |
|               |             |                      |              |          |       |             |                |                          |                |
| 7             | CTRI/2020/05/025088 | Arm 1: *Guduchi* | Randomized, parallel-group trial | N/A | Phase 1/2 | 1200        | Comparative assessment of occurrence of COVID-19 infection in healthy volunteers | CCRAS, New Delhi DCGI approval: N/A | AP |
|               |             | Arm 2: Standard prophylactic care |              |          |       |             |                |                          |                |
| 8             | CTRI/2020/05/025429 | Arm 1: *Ashwagandha standard prophylactic care* | Non-randomized, active controlled trial | Open label | Phase 2/3 | 5000        | Comparative assessment of occurrence of COVID-19 infection | NIMH (CCRAS), Hyderabad DCGI approval: N/A | TS |
|               |             | Arm 2: Standard prophylactic care |              |          |       |             |                |                          |                |

Contd...
| Serial number | CTRI number         | Intervention details | Study design                     | Blinding   | Phase   | Sample size | Primary outcome                                                                 | Sponsor and regulatory status                      | States and UTs |
|---------------|---------------------|----------------------|----------------------------------|------------|---------|-------------|--------------------------------------------------------------------------------|-----------------------------------------------------|----------------|
| 9             | CTRI/2020/05.025332 | Arm 1: *Ashwagandha* Arm 2: HCQ | Randomized, parallel-group, active controlled trial | Open label | Phase 2  | 400         | (i) Proportion of SARS-CoV-2 infection-free participants on completion of study <br> (ii) Proportion of participants contracting COVID-19 during the study period | Ministry of AYUSH; MH CSIR, New Delhi <br> DCGI approval: N/A | AP |
| 10            | CTRI/2020/05.025166 | Arm 1: *Ashwagandha* | Randomized, parallel-group trial | Open label | Phase 2/3 | 1200        | Comparative assessment of occurrence of COVID-19 infection                       | Ministry of AYUSH, AP New Delhi <br> DCGI approval: N/A | AP |
| 11            | CTRI/2020/05.025093 | Arm 1: *Yashtimadhu* | Other                            | N/A        | Phase 2/3 | 1200        | Comparative assessment of occurrence of COVID-19 infection                       | Ministry of AYUSH, AP New Delhi <br> DCGI approval: N/A | AP |
|               |                     | Combination interventions (n=10) |                                   |            |         |             |                                                                                  |                                                     |                |
| 12            | CTRI/2020/05.025171 | Arm 1: *Guduchi Ghana Vati* 2. Anu taila 3. Rock salt and turmeric 4. Ayush preventive guidelines Arm 2: Standard prophylactic care | Randomized, parallel-group trial | Open label | Phase 2  | 50000       | Improvement in *bala* of an individual <br> Immuno-stimulation leading to non-development of symptoms of COVID-19 in risk population exposed to infected individuals <br> (*Bala* will be assessed by using specialized proforma including dasvidhapareeksha and other questionnaires which will reveal the physical and mental health of an individual) | AIIA, New Delhi <br> DCGI approval: N/A | DL |

*Contd...*
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|----------------|-------------------------|----------------|
| 13            | CTRI/2020/05/025069 | Arm 1: Guduchi Ghana Vati (Sushamani Vati) or Sudarshana Ghanavati or Ashwagandha | Single-arm trial | Open label | Phase 3/4 | 1324 | Incidence of COVID-19-positive cases (as confirmed by RT-PCR) | CCRAS, New Delhi | DL (3 sites) |
| 14            | CTRI/2020/05/025482 | Arm 1: Curcumin with black pepper Arm 2: Standard treatment | Randomized, parallel-group trial | Investigator blinded | N/A | 50 | COVID-19 test and acute phase reactants such as D-dimer, CRP, LDH, CBC, ferritin, troponin, cardiac myoglobin, PT INR and appearance of respiratory symptoms | Siddhivinayak Pain Relief Center, Pune | MH |
| 15            | CTRI/2020/06/025637 | Arm 1: Piper betel with the combination of swarnabhasma (herbomineral combination) | Cluster randomized trial | Participant and investigator blinded | N/A | 10 | Complete blood picture, serum ferritin, C-reactive protein, LDH, troponin, nucleic acid amplification test and RT-PCR | ABVGMc, Vidisha | MP |
| 16            | CTRI/2020/05/025341 | Arm 1: Kiratiktadi Kwath; Ashwagandha churna; Yoga parallel-group trial exercises; immunobooster Ayush Kwath Arm 2: Standard treatment | Randomized | N/A | N/A | 30 | Efficacy in the management of mild and asymptomatic cases of COVID-19 patients | GS Ayurveda Medical College and Hospital, Ghaziabad | UP |
| 17            | CTRI/2020/04/024731 | Arm 1: Samshamani Vati, Sudarshan Ghana Vati, Khadiradi Vati, Muruchhika Tila Tila (for Nasya, Arsenic Album 30 Arm 2: Standard treatment | Single-arm trial | Open label | Phase 3 | 50 | Episodes and severity of symptoms of respiratory tract infection (cold, sore throat, dry cough, breathlessness) | Parul Institute of Ayurved, Vadodara | GJ |

*Contd...*
| Serial number | CTRI number     | Intervention details                                                                 | Study design                        | Blinding   | Phase | Sample size | Primary outcome                                                                                                                                  | Sponsor and regulatory status | States and UTs |
|---------------|----------------|--------------------------------------------------------------------------------------|-------------------------------------|------------|-------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|----------------|
| 18            | CTRI/2020/04/024882 | Arm 1: Kashaya (decoction) of *Tinospora cordifolia* stem, *Piper longum* fruit, and standard treatment  
Arm 2: Standard treatment | Non-randomized, active controlled trial | N/A        | Phase 3 | 60          | 1. Percentage of patients progressing to serious/critical stage of disease  
2. Progress of disease as per clinical severity score (COCSS)  
3. Number of days of treatment, hospitalization, type of care and site of treatment at hospital, oxygen support requirement, days of ventilation required, period of convalescence and return to normal life activity  
4. Number of days taken to test negative for COVID, total days to discharge from hospital  
5. Profiling according to *tridosha*  
6. Defining the disease according to Ayurveda | Ministry Of AYUSH, New Delhi | HR |
| 19            | CTRI/2020/05/025178 | Arm 1: Tab Samsamani *Vati*; Herbal tea; application of Anu taila; Haridra khanda  
Arm 2: Standard prophylactic care | Randomized, parallel-group trial | Open label | Phase 2 | 140         | Improvement in *bala* of an individual  
*Bala* will be assessed by using specialised proforma including *dashavideharpaksha* and other questionnaires which will reveal the physical and mental health of an individual | AIIA, New Delhi | DL |
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|----------------|--------------------------|--------------|
| 20            | CTRI/2020/05/025276 | Arm 1: Sanshamani Vati (Tinospora cordifolia); Nagaradi kwath (decoction of Zingiber officinale, Terminalia chebula and Tinospora cordifolia); Amalaki churna (powder of Phyllanthus emblica); Golden milk (milk with Curcuma longa) | Single-arm trial | N/A | Phase 3 | 50 | Time taken and number of patients progressing from asymptomatic to symptomatic condition | Ch Brahm Prakash Ayurved Charak Sansthan, New Delhi | DL |
| 21            | CTRI/2020/05/025398* | Arm 1: Kiratikadi Kwath (Astadashang Kwath) Sharangdhara Samhita - kwath prakaran; Ashwgandhachurna with milk; Yoga | Single-arm trial | N/A | N/A | 30 | 1. Efficacy in boosting Vyadhikshamatwa and prevention against communicable diseases. 2. Will help in overcoming the anxiety level and stress of HCQs | GS Ayurveda UP Medical College and Hospital, Hapur | UP |
| 22            | CTRI/2020/06/025557 | Arm 1: AYUSH-64 as add on to standard treatment  Arm 2: Yashtimadhu as add on to standard treatment  Arm 3. Sanshamani Vati Plus; as add-on standard treatment  Arm 4: Standard treatment | Randomized, parallel-group, active controlled trial | Open label | Phase 2 | 420 | 1. Mean time (days) for clinical recovery 2. Proportion of patients showing clinical recovery | Ministry of AYUSH, New Delhi | MH |
| 23            | CTRI/2020/05/025156 | Arm 1: AYUSH-64  Arm 2: Standard treatment | Randomized, parallel-group, active controlled trial | Open label | Phase 3/4 | 60 | Clinical cure rate: Time to negative conversion of SARS-CoV-2 | CCRAS, New Delhi | MH |
| 24            | CTRI/2020/05/025335 | Arm 1: AYUSH-64 | Single-arm trial | N/A | Phase 3 | 40 | 1. Mean time (days) for clinical recovery as per defined clinical recovery criteria 2. Number of patients showing ‘clinical recovery’ | CCRAS, New Delhi | DL |

Contd...
| Serial number | CTRI number       | Intervention details          | Study design                          | Blinding | Phase     | Sample size | Primary outcome                                                                 | Sponsor and regulatory status | States and UTs |
|--------------|------------------|-------------------------------|---------------------------------------|----------|-----------|-------------|---------------------------------------------------------------------------------|-------------------------------|----------------|
| 25           | CTRI/2020/05/025338 | Arm 1: AYUSH-64               | Single-arm trial                      | N/A      | Phase 2/3 | 40          | 1. Mean time (days) for clinical recovery as per defined clinical recovery criteria 2. Number of patients showing 'clinical recovery' | CCRAS, New Delhi DCGI approval: N/A | DL             |
| 26           | CTRI/2020/05/025214 | Arm 1: AYUSH-64               | Randomized, parallel-group, active controlled trial | Open label | Phase 2/3 | 80          | 1. Mean time (days) for clinical recovery (day of randomization to the day of clinical recovery) 2. Proportion of patients showing 'clinical recovery' | CCRAS, New Delhi DCGI approval: N/A | CH             |
| 27           | CTRI/2020/05/025484 | Arm 1: Chyawanprash           | Non-randomized, active controlled trial | Open label | Phase 2/3 | 5000        | Comparative assessment of occurrence of COVID-19 infection Percentage of participants with SARS CoV-2 positivity as estimated by RT-PCR of nasopharyngeal swab | NIMMH (CCRAS), Hyderabad DCGI approval: N/A | TS, DL         |
| 28           | CTRI/2020/05/025425 | Arm 1: Chyawanprash           | Single-arm trial                      | N/A      | Phase 3/4 | 50          | 1. Comparative assessment of incidence of COVID-19 2. Comparative assessment of incidence of other non-COVID-19 infections | CCRAS, New Delhi DCGI approval: N/A | DL             |
| 29           | CTRI/2020/05/024981 | Arm 1: Chyawanprash with milk | Randomized, parallel-group trial      | Open label | N/A      | 600         | 1. Comparative assessment of incidence of COVID-19 2. Comparative assessment of incidence of other non-COVID-19 infections | Dabur India Ltd, Ghaziabad DCGI approval: N/A | GJ (2 sites), MH (2 sites), RJ |
| 30           | CTRI/2020/05/025275 | Arm 1: Chyawanprash           | Randomized, parallel-group trial      | N/A      | Phase 3   | 200         | Percentage of participants with SARS CoV-2 positivity as estimated by RT-PCR | CCRAS, New Delhi DCGI approval: N/A | DL             |
| 31           | CTRI/2020/06/025592 | Arm 1: Shakti drops; turmeric plus; Tulsi arka | Single-arm trial                      | Open label | Phase 3/4 | 50          | Recovery in the signs and symptoms as fever and respiratory distress | Sri Sri Tattva, Bangalore DCGI approval: N/A | KA             |
| Serial number | CTRI number          | Intervention details                                                                 | Study design                  | Blinding                  | Phase | Sample size | Primary outcome                                                                                           | Sponsor and regulatory status                              | States and UTs |
|--------------|----------------------|----------------------------------------------------------------------------------------|-------------------------------|---------------------------|-------|-------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|----------------|
| 32           | CTRI/2020/06/025590  | Arm 1: Astha-15 capsule and standard treatment Arm 2: Placebo and standard treatment  | Randomized, parallel-group, placebo-controlled trial | Participant, investigator and outcome assessor blinded | Phase 3 | 120         | 1. Changes in scores of the St. George Respiratory Questionnaire from baseline to EOT visit 2. Changes in scores of the Leicester Cough Questionnaire from baseline to EOT visit | Dalmia Centre for Research and Development, Noida DCGI approval: N/A | AP, RJ, DL, MH |
| 33           | CTRI/2020/05/025483  | Arm 1: Clevira tablet Arm 2: Standard treatment                                         | Randomized, parallel-group trial | N/A                       | Phase 3/4 | 100         | 1. Time taken for clinical recovery, which is defined as: (i) normalization of pyrexia and body pain; (ii) respiratory rate <24/minute; (iii) SpO2 rate >94%; (iv) relief from cough and maintenance of above for > 72 h 2. Proportion of patients with swabs negative for COVID-19 in RT-PCR at day 5, 10 and 15 3. Reduction of viral load | Apex Laboratories Pvt Ltd, Chennai DCGI approval: N/A | TN |
| 34           | CTRI/2020/05/025334  | Arm 1: SUVED + Reimmungen                                                                | Single-arm trial              | N/A                       | Phase 2 | 30          | Prevention of onset or complications of COVID-19 infection                                               | Health Solutions, Pune DCGI approval: N/A                  | MH |
| 35           | CTRI/2020/05/025343  | Arm 1: SUVED + Reimmungen                                                                | Single-arm trial              | N/A                       | Phase 2/3 | 30          | Mortality                                                                                               | Health Solutions, Pune DCGI approval: N/A                  | MH |
| 36           | CTRI/2020/05/025340  | Arm 1: ShatPlus and standard treatment Arm 2: Standard treatment                        | Randomized, parallel-group trial | Open label                | Phase 1/2 | 60          | 1. Number of days for negative PCR confirmatory test from nasopharyngeal swab for SARS-CoV-2 2. Serum levels of CD4, CD8, NK cell panel CD16/CD56, CRP, IgM, IgG | BVG Life Sciences Ltd, Pune DCGI approval: N/A              | MH |

Contd...
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|----------------|--------------------------|----------------|
| 37            | CTRI/2020/05/025161 | Arm 1: Aayudh advance bacteria, viruses  
Arm 2: Standard treatment | Randomized, parallel-group, active controlled trial | Open label | Phase 2 | 120 | 1. Rate of recovery  
2. Symptom resolution: fever  
3. Symptom resolution: cough  
4. Symptom resolution: shortness of breath | Shukla Ashar Impex Pvt Ltd, Rajkot  
DCGI approval: N/A | GJ |
| 38            | CTRI/2020/04/024883 | Arm 1: ZingiVir H  
Arm 2: N/A | Other | Outcome assessor blinded | Phase 4 | 112 | The odds of ratio for improvement on a 7-point ordinal scale on day 15  
Each day, the worst score from the previous day will be recorded | Pankajakasthuri Herbal Research Foundation, Thiruvananthapuram  
DCGI approval: N/A | KA (2 sites), MH |
| 39            | CTRI/2020/05/024967 | Arm 1: MyVir tablets  
Arm 2: Standard treatment | Single-arm trial | N/A | Post marketing surveillance | 30 | Improvement in patients who are assessed daily for symptoms which include cough, fever with or without chills and difficulty in breathing for the period they are in quarantine | Mi Lab LifeSciences Pvt Ltd, Bengaluru,  
DCGI approval: N/A | KA |
| 40            | CTRI/2020/06/025527 | Arm 1: Amrta Karuna syrup  
Arm 2: Standard treatment | Non-randomized, active controlled trial | N/A | Post marketing surveillance | 30 | 1. Improvement in patients who are assessed daily for symptoms which include cough, fever with or without chills and difficulty in breathing  
2. Early recovery and reduced mortality | Voppec Pharmaceuticals Pvt Ltd, Chennai  
DCGI approval: N/A | KA |
| 41            | CTRI/2020/05/025326 | Arm 1: Tab Pinak | Single-arm trial | N/A | Phase 2 | 30 | Early recovery and reduced mortality | Shree Bharadi Ayurvedic, Maharashtra  
DCGI approval: N/A | MH |

Contd...
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|-----------------|-------------------------------|----------------|
| 42            | CTRI/2020/05/025273 | Arm 1: Tablet pure Ashwagandha 500 mg; Pure Giloy extract; tablet pure tulsi extract; Anu Taila; Swasari Ras Arm 2: Placebo therapy | Randomized, parallel-group, placebo-controlled trial | NIL | N/A | 120 | Virological clearance as measured by RT-PCR of nasopharyngeal swab | Patanjali Research Institute, Haridwar; NIMS, Jaipur DCGI approval: N/A | RJ |
| 43            | CTRI/2020/05/025222 | Arm 1: AOIM - Z Tablet | Single-arm trial | N/A | Phase 4 | 275 | Prevention of incidence of COVID-19 infection | Shree Dhootapapeshwar Limited, Mumbai DCGI approval: N/A | MH |
| 44            | CTRI/2020/05/025434 | Arm 1: Zingivir-H | Randomized, parallel-group, placebo-controlled trial | Outcome assessor blinded | Phase 4 | 135 | The odds of ratio for improvement on a 7-point ordinal scale on day 15 and clearance of medically attended lung infection due to RT-PCR confirmed COVID-19 infection | Pankajakshuri Herbal Research Foundation, Thiruvananthapuram DCGI approval: N/A | KA (2 sites), MH |
| 45            | CTRI/2020/06/025556 | Arm 1: Virulina Arm 2: Standard treatment | Randomized, parallel-group, placebo-controlled trial | Participant and investigator blinded | N/A | 30 | 1. Time to a negative SARS-CoV-2 RT-PCR result of both oropharyngeal swab and nasopharyngeal swab. 2. Clinical cure based on clinician’s assessment of symptoms a. Change in positive COVID-19 status on day 8 and day 15 3. Clinical outcomes a. Proportion of patients on WHO progression scale 0 to 10 on day 8 and day 15 | Natural Solutions, Mumbai DCGI approval: N/A | AP |

Contd...
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|----------------|--------------------------------|----------------|
| 46            | CTRI/2020/06/025523 | Arm 1: Meditation and breathing exercises and standard treatment  
Arm 2: Standard treatment | Randomized, parallel-group trial | N/A | N/A | 84 | Depression, anxiety and stress levels in patients assessed using DASS-21 questionnaire | National Cancer Institute, Jhajjar  
DCGI approval: N/A | HR |
| 47            | CTRI/2020/05/025162  | Arm 1: Alternate nostril breathing and guided meditation; (1) *Nadi Shodhan Pranayama*; (2) *Panchakosha* meditation  
Arm 2: The control group will not receive the intervention. | Randomized, parallel-group trial | N/A | N/A | 200 | PSQI for sleep quality | JIPMER, Puducherry  
DCGI approval: N/A | PY |
| 48            | CTRI/2020/05/025320* | Arm 1: Yoga and Naturopathy, immune-boosting agents such as ginger Tulsi pepper, Adhimaduram, turmeric, gargling, steam inhalation, Sun bath aromatherapy  
Arm 2: Standard treatment | Nonrandomized, active controlled trial | N/A | Phase 3/4 | 658 | Time to progress to next stage of severity *i.e.*, from asymptomatic/uncomplicated/mild pneumonia to moderate/severe stages | Government Yoga And Naturopathy Medical College, Chennai  
DCGI approval: N/A | TN (4 sites) |
| 49            | CTRI/2020/06/025650  | Arm 1: *Joshanda* (decoction) of the following: *Behidana* (*Cydonia oblonga*), *Unnab* (*Zizyphus jujube*), *Sapistan* (*Coriandrum myxa*) and *Khameera Marwareed*  
Arm 2: *Joshanda* (decoction) and *Tiryaq e Arba*  
Arm 3: Standard prophylactic care | Other | Open label | Phase 2 | 4000 | 1. Incidence of COVID-19 cases  
2. Improvement in immune status using ISQ | Ministry of AYUSH, KA  
New Delhi  
DCGI approval: N/A | KA |
| 50            | CTRI/2020/05/025254  | Arm 1: *Joshanda* (decoction) and *Khameera Marwareed*  
Arm 2: *Joshanda* (decoction) and *Tiryaq e Arba*  
Arm 3: Standard prophylactic care | Non-randomized, multiple-arm trial | N/A | Phase 3 | 40000 | 1. Incidence of COVID-19 cases  
2. Improvement in immune status using ISQ | CCRUM, New Delhi  
UP, KA, TS, JK, MH, DL  
DCGI approval: N/A | MH, DL |

*Contd...*
| Serial number | CTRI number         | Intervention details                                                                 | Study design          | Blinding          | Phase      | Sample size | Primary outcome                                                                                                                                                                                                 | Sponsor and regulatory status                                                                 | States and UTs |
|--------------|---------------------|---------------------------------------------------------------------------------------|-----------------------|-------------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------|
| 51           | CTRI/2020/06/025625 | Arm 1: Kabasura Kadineer and Bramanandhabairavam                                        | Other                 | Open label        | Phase 2    | 86          | Proportion of patients confirmed as negative for SARS-CoV-2 in two consecutive throat/nasal swabs (taken 24 h apart) at day 15/day16 | Eminentlabs Business Solutions Pvt Ltd, Chennai                                            | TN             |
| 52           | CTRI/2020/05/025298 | Arm 1: Kabasura Kadineer Nilavembukudineer; Arm 2: Standard prophylactic care          | Non-randomized, active controlled trial | N/A               | N/A        | 21500       | Occurrence of COVID-19 infection                                                                                                                | CCRS, Chennai; Ministry of AYUSH, New Delhi                                               | TN             |
| 53           | CTRI/2020/05/025215 | Arm 1: Kabasura Kadineer Arm 2: Vitamin C, zinc supplementation                         | Randomized, parallel-group trial | Open label        | Phase 1/2  | 50          | Reduction in incidence of clinical symptoms of COVID-19, negative conversion of SARS-CoV-2, reduction in viral load of SARS-CoV-2 at the end of treatment and examine the levels immune markers and inflammatory markers | Government Stanley Medical College, Chennai                                               | TN             |
| 54           | CTRI/2020/06/025530 | Arm 1: Aconite 30 + Arsenic album 30 + Allium cepa 30 + Influenzum 30 + Gelsmium 30 + Eupatorium 30 + Echinacia 0 + Thuja 0 | Non-randomized, active controlled trial | N/A               | N/A        | 10000       | Number of patients with viral fever/COVID-19                                                                                                       | Cancer Aid Society, Lucknow                                                             | UP             |
| 55           | CTRI/2020/05/025491 | Arm 1: Arsenic album 30c Arm 2: Bryonia alba 30c Arm 3: Camphora 1M Arm 4: Coronavirus-related nosodes (30c potency); Arm 5: Matching placebo pills | Cluster randomized trial | Participant and outcome assessor blinded | Phase 2    | 1000        | Number of patients turning symptomatic                                                                                                               | Life Force Foundation Trust, Mumbai                                                      | MH             |

Contd...
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|-----------------|-----------------------------|----------------|
| 56            | CTRI/2020/05/025272 | Arm 1: Arsenicum album 30  
Arm 2: No. 40 size globules medicated with alcohol 90% v/v is used as placebo | Cluster randomized trial | Participant and investigator blinded | N/A | 800 | COVID-19 in quarantined persons | Government Homeo Dispensary, Kerala  
DCGI approval: N/A | KL |
| 57            | CTRI/2020/05/025205 | Arm 1: Arsenicum album 30c  
Arm 2: No intervention | Cluster randomized trial | N/A | Phase 2/3 | 33000 | Confirmation of diagnosis for COVID-19 infection based on RT-PCR/end of quarantine period | CCRH, New Delhi  
DCGI approval: N/A | TN, DL, AP, TS, RJ, WB, KL, MH, UP, GJ |
| 58            | CTRI/2020/05/025049 | Arm 1: Arsenicum album 30c | Cluster randomized trial | Open label | Phase 2/3 | 100 | Clinical recovery (COVID-19 negative) or death | Sai Nidan Homeopathy Clinic, Chhattisgarh  
DCGI approval: N/A | CG |
| 59            | CTRI/2020/05/024986 | Arm 1: Arsenicum album 30c | Single-arm trial | N/A | N/A | 10000 | Confirmation of diagnosis for COVID-19 infection/end of quarantine period as per standard protocol | CCRH, New Delhi  
DCGI approval: N/A | DL |
| 60            | CTRI/2020/05/024969 | Arm 1: Arsenicum album 30c (variable dose potency and frequency) and standard treatment  
Arm 2: Placebo and standard treatment | Randomized, parallel-group, placebo-controlled trial | Open label | Phase 2/3 | 100 | Clinical outcome in terms of recovery of patient or requirement of life support (ventilator)/death | Naiminath Homoeopathic Medical College Hospital and Research Centre, Agra  
DCGI approval: N/A | UP |
| 61            | CTRI/2020/04/024926 | Arm 1: Arsenicum album, Bryonia alba, Gelsemium, Antimonium tartaricum, Crotalus horridus  
Arm 1: Arsenicum album, Bryonia alba, Gelsemium, Antimonium tartaricum, Crotalus horridus | Single-arm trial | Participant blinded | Phase 3 | 100 | Clinical recovery (COVID-19 negative) or appearance of symptoms requiring conventional treatment | Naiminath Homoeopathic Medical College Hospital and Research Centre, Agra  
DCGI approval: N/A | UP |

Contd...
| Serial number | CTRI number       | Intervention details                                                                 | Study design                              | Blinding                        | Phase   | Sample size | Primary outcome                                                                                           | Sponsor and regulatory status                                | States and UTs |
|---------------|-------------------|---------------------------------------------------------------------------------------|-------------------------------------------|---------------------------------|---------|-------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|---------------|
| 62            | CTRI/2020/04/024905 | Arm 1: Arsenic album, *Bryonia alba*, *Gelsemium*, *Antimonium tartaricum*, *Crotalus horridus*  
Arm 2: Placebo | Randomized, parallel-group, placebo-controlled trial                                  | Participant blinded                       | Phase 3  | 100         | Clinical recovery (COVID-19 negative) or death.                                                         | Naiminath Homoeopathic Medical College Hospital and Research Centre, Agra  
DCGI approval: N/A | UP             |
| 63            | CTRI/2020/04/024857 | Arm 1: Arsenic album, Camphora, *Bryonia alba*, *Helleborus niger*, *Justicia adhatoda*  
Arm 2: Identical placebo | Cluster randomized trial                                                               | Open label                                 | Phase 1/2 | 100         | Percentage of patient admissions to critical care                                                      | Welling Healthcare Private Limited, Mumbai  
DCGI approval: N/A | MH             |
| 64            | CTRI/2020/06/025558 | Arm 1: *Bryonia alba 30C*  
Arm 2: Identical placebo | Randomized, parallel-group, placebo-controlled trial                                  | Participant and investigator blinded      | Phase 4  | 300         | Prophylactic effect                                                                                     | Aarogya Homoeopathic Medical College and Hospital, Jaipur; Ministry of AYUSH, New Delhi  
DCGI approval: N/A | RJ             |
| 65            | CTRI/2020/04/024947 | Arm 1: Cadamba 200                                                                   | Randomized, parallel-group, active controlled trial | N/A                | Phase 3  | 100         | Serologically negative blood test for COVID-19                                                          | PI initiated, Homeo clinic, Gondia-Maharashtra  
DCGI approval: N/A | MH             |
| 66            | CTRI/2020/05/025496 | Arm 1: CNV01                                                                         | Single-arm trial                          | Open label                   | Phase 1  | 10          | Safety measure in terms of investigations (PCR) blood parameters                                      | Life Force Foundation Trust, Mumbai  
DCGI approval: N/A | MH             |

Contd...
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|-----------------|--------------------------|----------------|
| 67            | CTRI/2020/04/024925 | Arm 1: Homoeopathic medicine and standard treatment  
Arm 2: Placebo and standard treatment | Randomized, parallel-group, placebo-controlled trial | Open label | Phase 2 | 100 | Clinical recovery of patient or requirement of life support (ventilator)/death | Bajaj Auto Ltd, Maharashtra  
DCGI approval: N/A | MH (2 sites) |

*Registered trials as on June 5, 2020. Trials with combination therapy (involving more than one system of AYUSH) are mentioned in only one category to avoid duplication. AYUSH includes Ayurveda, Yoga, Unani, Siddha, Homeopathy trials. Table data are as per information provided by trialist. The keyword ‘Standard treatment’ and has been used for uniformity and includes the following category as mentioned by the trialist i.e., standard of care, standard care of treatment and supportive management, standard treatment protocol, local-level standard treatment, best supportive care, treatment guidelines as per MOHFW. The term ‘Standard prophylactic care’ has been used for uniformity which represents the terminologies used by the trialist for standard preventive measures against COVID-19. AAIA, All India Institute of Ayurveda; ABVGMC, Atal Bihari Vajpayee Government Medical College; AYUSH, Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy; COVID-19, coronavirus disease 2019; CCRAS, Central Council for Research in Ayurvedic Sciences; CCRUM, Central Council for Research in Unani Medicine; CCRS, Central Council for Research in Siddha; CCHR, Central Council for Research in Homoeopathy; CSIR, Council of Scientific and Industrial Research; IPGTRA, Institute for Post Graduate Teaching and Research in Ayurveda; JIPMER, Jawaharlal Institute of Postgraduate Medical Education and Research; NIA, National Institute of Ayurveda; NIHMH (CCRAS), National Institute of Indian Medical Heritage (CCRAS); NIMS, National Institute of Medical Sciences Jaipur; PI, Principal investigator; N/A, not applicable; ISQ, immune status questionnaire; PSQI, Pittsburgh Sleep Quality Index; HCQ, healthcare worker; RT-PCR, reverse transcription polymerase chain reaction; DASS-21, depression, anxiety and stress scale - 21 items; DCGI, Drugs Controller General of India; CRF, C-reactive protein; LDH, lactate dehydrogenase; CBC, complete blood count; PT INR, prothrombin time international normalized ratio; NK, natural killer. States and Union Territories (UTs): AP: Andhra Pradesh; AR: Arunachal Pradesh; AS: Assam; BR: Bihar; CG: Chhattisgarh; GA: Goa; GJ: Gujarat; HR: Haryana; HP: Himachal Pradesh; JK: Jammu and Kashmir; JH: Jharkhand; KA: Karnataka; KL: Kerala; MP: Madhya Pradesh; MH: Maharashtra; MN: Manipur; ML: Meghalaya; MZ: Mizoram; N: Nagaland; OR: Odisha; PB: Punjab; RJ: Rajasthan; SK: Sikkim; TN: Tamil Nadu; TR: Tripura; UK: Uttarakhand; UP: Uttar Pradesh; WB: West Bengal; TS: Telangana; AN: Andaman and Nicobar Islands; CH: Chandigarh; DH: Dadra and Nagar Haveli; DD: Daman and Diu; DL: Delhi; LD: Lakshadweep; PY: Puducherry
Table IV. Details of miscellaneous trials (n=13) on coronavirus disease 2019 registered in the Clinical Trials Registry - India

| Serial number | CTRI number      | Intervention details                                                                 | Study design                | Blinding | Phase | Sample size | Primary outcome                                                                 | Sponsor and regulatory status                          | States and UTs |
|---------------|-----------------|--------------------------------------------------------------------------------------|-----------------------------|----------|-------|-------------|--------------------------------------------------------------------------------|--------------------------------------------------------|---------------|
| 1             | CTRI/2020/05/025248 | Arm 1: Brief tele-counselling model for coping with psychological concerns associated with COVID-19 | Non-randomized, N/A multiple-arm trial | N/A       | N/A   | 128         | Anxiety (assessed as a continuous variable on HADS)                           | PI initiated, MB Hospital RNT Medical College Udaipur DCGI approval: N/A | RJ            |
| 2             | CTRI/2020/05/025492 | Arm 1: Tele-consultation Arm 2: Standard arm with routine follow up visits | Randomized, parallel-group trial | Open label | N/A   | 2978        | Need for emergency room visit or re-hospitalization                           | JIPMER, Puducherry DCGI approval: N/A                   | PY            |
| 3             | CTRI/2020/05/025331 | Arm 1: Home-based prehabilitation | Non-randomized, active controlled trial | NIL       | N/A   | 15          | Change in emotional functioning by DASS-21, physical functioning by change in performance score (Karnofsky Performance Scale) score and change in respiratory functional parameters | AIIMS, New Delhi DCGI approval: N/A                  | DL            |
| 4             | CTRI/2020/05/024962 | Arm 1: Povidone-iodine gargles and intranasal application Arm 2: Normal saline | Randomized, parallel-group trial | N/A       | N/A   | 96          | Comparing the reduction in the progression, transmission of disease assessed by viral load | Win Medicare Pvt Ltd, Vijaywada DCGI approval: N/A       | AP            |
| 5             | CTRI/2020/05/024983 | Arm 1: Topical lignocaine lozenges | Single-arm trial | N/A       | N/A   | 30          | Sensitivity of nasal and throat swabs for RT-PCR of COVID-19 after topical lignocaine use | AIIMS, New Delhi DCGI approval: N/A                   | DL            |
| 6             | CTRI/2020/04/024776 | Arm 1: Chest X-ray artificial intelligence module Arm 2: CT- scan of thorax AI module Arm 3: Voice sampling AI module Arm 4: Normal individuals’ chest X-ray, CT-scan thorax and voice sampling | Non-randomized, multiple-arm trial | N/A       | N/A   | 1650        | Assess sensitivity and specificity of AI module by performing chest X-ray, CT-thorax and voice sampling | PI initiated RNT Medical College, Udaipur DCGI approval: N/A | RJ (2 sites)   |
| Serial number | CTRI number | Intervention details | Study design | Blinding | Phase | Sample size | Primary outcome | Sponsor and regulatory status | States and UTs |
|---------------|-------------|----------------------|--------------|----------|-------|-------------|-----------------|-----------------------------|----------------|
| 7             | CTRI/2020/05/025071 | Arm 1: Lowest driving pressure-guided PEEP Arm 2: Conventional lung protective ventilation strategy | Randomized, parallel-group trial | Participant blinded | Phase 3 | 40 | Difference in the area under the curve (adjusted to survival time) for Murray’s lung injury score in the first 4 days | AIIMS, New Delhi DCGI approval: N/A | DL |
| 8             | CTRI/2020/05/025489 | Arm 1: CMAC video laryngoscope Arm 2: McGrath MAC video laryngoscope | Randomized, parallel-group trial | Participant and outcome assessor blinded | N/A | 60 | Time to intubation | AIIMS, New Delhi DCGI approval: N/A | DL |
| 9             | CTRI/2020/06/025522 | Arm 1: Touren non-channelled video laryngoscope Arm 2: King Vision channelled video laryngoscope | Randomized, cross-over trial | Outcome assessor blinded | N/A | 50 | Time to intubation | AIIMS, New Delhi DCGI approval: N/A | DL |
| 10            | CTRI/2020/06/025589 | Arm 1: COVID barrier box with Ambu King vision video laryngoscope Arm 2: COVID barrier box with Macintosh laryngoscope | Randomized, parallel-group, active controlled trial | NIL | N/A | 60 | Intubation time | AIIMS, Bhubaneswar DCGI approval: N/A | OR |
| 11            | CTRI/2020/04/024747 | Arm 1: Simulation-based training of ventilatory management of COVID-19 patients | Single-arm trial | Participant and outcome assessor blinded | N/A | 26 | Prepare a module for non-anaesthesiology trainees to handle ventilators in COVID-19 patients | GSL Medical College, Rajahmundry DCGI approval: N/A | AP |
| 12            | CTRI/2020/05/025490 | Arm 1: Chlorpromazine + NBE extract concoction + cholecalciferol + *Azadirachta indica* bark extract concoction + *Arsenicum album* tea + Arm 2: Standard treatment | Randomized parallel-group active controlled trial | Participant and investigator blinded | Phase 2/3 | 110 | Protection from COVID-19 infection | Siddhartha Hospital, Agra DCGI approval: N/A | UP |

Contd...
In addition, with respect to the growing body of scientific data, regarding risks associated with the use of HCQ, particularly QTc prolongation and cardiac arrhythmias, a Phase 2 trial is underway to assess the effect of topical i.e., nasal application of chloroquine in early-stage COVID-19 on viral load and cure rates (CTRI/2020/04/024729).

### Immunomodulators

**Ciclesonide:** A Phase 2 trial being conducted at a government medical college in New Delhi plans to evaluate not only the effects of HCQ but also that of ciclesonide, a glucocorticoid, and ivermectin, an anthelmintic drug, in 120 patients with moderate COVID-19 infection (CTRI/2020/04/024948).

**Imatinib:** Imatinib, which inhibits BCR - ABL tyrosine kinase, revolutionized the treatment of chronic myelogenous leukaemia. Imatinib has been reported to significantly reduce titres of SARS-CoV and Middle East respiratory syndrome (MERS)-CoV, which depend on ABL kinase activity to fuse and enter into the cells. An open-label, randomized, parallel-group Phase 2 trial with imatinib in 100 patients with mild COVID-19 has been registered in the CTRI (CTRI/2020/04/024806).

**Itolizumab:** This is an anti-CD6 humanized monoclonal IgG1 antibody which acts upstream by inhibiting the co-stimulation of T cells, resulting in decreased release of signature cytokines of Th1 and Th17 cells. Sponsored by an Indian pharmaceutical company, this open-label, randomized, parallel-group Phase 2 trial with itolizumab in 100 patients with mild COVID-19 has been registered in the CTRI (CTRI/2020/04/024806).

**Tocilizumab:** Interleukin-6 (IL-6) is believed to play an important role in this syndrome, and an IL-6 receptor blocker, tocilizumab, has generated global interest as a potential agent for patients with severe COVID-19. A multicentric, randomized, Phase 3 trial to evaluate the clinical outcomes and safety of tocilizumab along with standard of care in patients with cytokine release syndrome associated with moderate-to-severe COVID-19 infection has been registered in the CTRI (CTRI/2020/05/025369).

**Mycobacterium w:** It is a saprophytic cultivable mycobacterium which is a potent immunomodulator. When used as an adjuvant to multidrug therapy, it has been reported to have significant benefits in patients...
with tuberculosis, leprosy and HIV-AIDS\textsuperscript{16,17}. Three industry-sponsored trials are proposed to be undertaken with this agent in 40 critically ill COVID-19 patients, 480 hospitalized but not critically ill patients as well as 4000 individuals at high risk of contracting the disease. In addition, a Phase 2 observational study with heat killed \textit{Mycobacterium w} as add-on therapy is also underway on 50 hospitalized COVID-19 patients at a private medical college (CTRI/2020/05/025350).

Melatonin: Melatonin is a remarkably safe and established anti-inflammatory and anti-oxidative molecule with significant evidence suggesting its potential for limiting virus-related diseases, which may extend to COVID-19 as well\textsuperscript{18}. Melatonin has also been reported to possess significant immunomodulatory effects in cancer\textsuperscript{19}. A clinical trial on melatonin is underway to evaluate its role on COVID-19 infection rate along with immune response in high-risk groups after eight weeks of treatment (CTRI/2020/06/025613).

\textbf{Anthelmintics}

Ivermectin: This broad-spectrum antiparasitic agent has been shown to have potent \textit{in vitro} antiviral activity against a variety of viruses. In \textit{in vitro} studies, a single dose has been shown to bring a significant reduction in the replication of SARS-CoV-2\textsuperscript{20}. This has generated interest in the possibility of repurposing the drug for the management of COVID-19. A total of four clinical trials (CTRI/2020/04/024858, CTRI/2020/05/025068, CTRI/2020/05/025224, CTRI/2020/05/025333) with ivermectin are underway, three of which aim to establish the therapeutic efficacy of ivermectin in COVID-19 patients. The fourth trial is investigating the prophylactic effect of ivermectin on 2000 healthcare workers or healthy contacts (including children) of COVID-19 patients. The primary outcome for this study is resolution of signs and symptoms of COVID-19 and negative reverse transcription-polymerase chain reaction (RT-PCR) done 48 h after drug administration.

Niclosamide: Used to treat tapeworm infestation, niclosamide inhibits ATP production by uncoupling of oxidative phosphorylation. It has been reported to have \textit{in vitro} antiviral activity\textsuperscript{21,22}. A randomized, parallel-group trial which proposes to investigate the virologic cure rates of niclosamide in patients with mild-to-very mild COVID-19 infection has been registered (CTRI/2020/04/024949).

\textbf{Antihypertensive}

Losartan: Angiotensin-converting enzyme 2 (ACE2) is a functional receptor for SARS-CoV-2 infection and in the process causes internalization and destruction of ACE2\textsuperscript{23}. The major complications of COVID-19 are possibly caused by excessive angiotensin II activation due to loss of ACE2 and can be potentially reversed by angiotensin receptor blockers such as losartan\textsuperscript{24}. A randomized, parallel-group, placebo-controlled trial of losartan for the prevention of COVID-19 complications has been registered and is being conducted in an academic setting (CTRI/2020/05/025319).

\textbf{Antioxidant/pro-oxidant agent}

Resveratrol-copper and sodium-copper-chlorophyllin: It has been hypothesized that following microbial infection, cell-free chromatin (cfCh) particles are released from dying cells, causing apoptosis and inflammation in the adjoining host cells. This process triggers a vicious cycle leading to sepsis\textsuperscript{25}. The novel pro-oxidant combination of resveratrol and copper has been reported to inactivate cfCh and demonstrated improved survival in animal models of sepsis\textsuperscript{26}.

The commonly used food colorant and dietary supplement, sodium copper chlorophyllin (SCC), has been reported to have significant antimutagenic and antioxidant properties\textsuperscript{27}. Two trials with resveratrol-copper and SCC as add-on treatment to standard treatment in asymptomatic/mildly symptomatic patients (Phase 3 trial) as well as hospitalized patients (Phase 2 trial) with COVID-19 have been registered (CTRI/2020/05/025336, CTRI/2020/05/025337).

\textbf{Antineoplastic}

2-deoxy-D-glucose (2-DG): A glucose analogue, 2-deoxy-D-glucose, is believed to have profound effects on a range of diseases such as cancer, viral infection and ageing-related morbidity\textsuperscript{28}. Recent \textit{in vitro} studies suggest the potential benefits of using 2-DG to mitigate COVID-19 infection\textsuperscript{29,30}. A Phase 2 trial to determine the safety and efficacy of the drug as an adjunctive therapy to standard of care in patients with moderate-to-severe COVID-19 is underway at 12 sites (CTRI/2020/06/025664).

\textbf{Phytopharmaceutical products}

\textit{Purified aqueous extract of Cocculus hirsutus (AQCH)}

An industry-sponsored trial has been registered with aqueous extract of \textit{Cocculus hirsutus} which is a phytopharmaceutical product derived from the tropical, climbing shrub \textit{C. hirsutus}. This plant has been reported to have significant medicinal properties in a variety of disease conditions including viral
infection\textsuperscript{31}. The trial is proposed to be conducted at 14 sites across the country on patients with moderate COVID-19 (CTRI/2020/05/025397).

**Thymoquinone**

*Nigella sativa*, commonly known as black cumin, has shown a wide spectrum of biological activities, the most prominent being antioxidant, anti-inflammatory and antimicrobial activities\textsuperscript{32}. An open-label, two-arm, parallel study is being conducted to evaluate the efficacy and safety of thymoquinone, a phytopharmaceutical compound extracted from *Nigella sativa* seeds, compared to best supportive care in patients with COVID-19 (CTRI/2020/05/025167).

**Cell- and plasma-based therapies**

**Convalescent plasma therapy (CPT)**

For immediate short-term immunity, convalescent plasma therapy (CPT) has generated particular interest as it appears to be safe, to be clinically effective and reduces mortality in times of large-scale epidemics\textsuperscript{33-35}. The ICMR has developed a protocol, which is approved by the Drugs Controller General of India, for a multicentre trial (PLACID trial) to test the efficacy of convalescent plasma obtained from recovered COVID-19 patients for administration to moderately ill COVID-19 patients. This is a multicentre, randomized, parallel-group, open-label, active controlled Phase 2 trial to be conducted on 452 patients at 39 sites in India (CTRI/2020/04/024775). In addition, two other trials have been registered which are being conducted by private hospitals on 100 patients each (CTRI/2020/04/024915, CTRI/2020/05/025328). Further, five additional small trials have also been registered investigating the role of CPT in hospitalized severely ill COVID-19 patients (CTRI/2020/04/024706, CTRI/2020/04/024804, CTRI/2020/05/025299, CTRI/2020/05/025346, CTRI/2020/05/025209).

**Cytokine cocktail therapy**

A Phase 1 trial to evaluate the safety and tolerability of cytokine cocktail therapy in healthy volunteers from healthy donors (derived by T cells) has been registered (CTRI/2020/05/025432). This trial is being conducted at Bengaluru, Karnataka.

**Biological products**

**Vaccines**

As per reports, vaccine against COVID-19 is being developed in about 90 institutions worldwide\textsuperscript{36}. Bacille Calmette-Guérin (BCG) is believed to stimulate the general immune response with a consequent faster response to infections that could reduce the severity of disease and lead to quicker recovery rates\textsuperscript{37}. In India, mass immunization with BCG has been underway since 1948\textsuperscript{38}. The global interest in BCG was recently sparked when Miller et al\textsuperscript{39}, reported a negative correlation between BCG immunization status of a country and mortalities due to COVID-19. In the CTRI, currently, there are three BCG vaccine trials registered. One of these is on the BCG-Denmark (Green Signal) vaccine for the prevention of COVID-19 in 1826 healthcare workers, whereas the other is a Phase 3 trial of recombinant BCG VPM1002 vaccine for the reduction in infection incidence and severity of COVID-19 in 5946 high risk individuals. Both these trials are triple-blinded, randomized, parallel-group, placebo-controlled trials (CTRI/2020/04/024833 and CTRI/2020/04/024749, respectively). A single-blind, single-centre Phase 2 trial on 60 patients, is evaluating the therapeutic efficacy of BCG in COVID-19 (CTRI/2020/05/025013).

**Traditional medicine**

During this pandemic, the potential of traditional medicine is being actively explored through the conduct of clinical trials to identify prophylactic as well as therapeutic agents. The AYUSH approach to manage the outbreak broadly comprises: preventive and prophylactic, symptom management of COVID-19-like illnesses and add-on interventions to the conventional care\textsuperscript{40}. Trials in the AYUSH system of medicine have been registered in the CTRI (n=67) and include Ayurveda (n=45), Yoga and Naturopathy (n=3), Unani (n=2), Siddha (n=3), Homeopathy (n=14) trials (Table III).

**Ayurveda**

Ayurveda is a comprehensive system of medicine that has been practiced in India for >5000 years\textsuperscript{41}. A total of 45 Ayurveda trials (Tables I and III) are currently registered in the CTRI. These are categorized as individual agents (11 trials) or combination preparations (10 trials, of which 3 trials include other systems of AYUSH such as homeopathy and/or yoga) as available under classical interventions. In addition, there are 24 trials registered on patented ayurvedic products. Four major plant products are under investigation, namely *Tinospora cordifolia*, *Withania somnifera*, *Glycyrrhiza glabra* and *Curcuma longa* (only in combination with other agents).

While the classical interventions, individual and combination trials (n=21), are mostly designed to
assess their prophylactic efficacy (n=16) in either healthy human volunteers in the community or those at risk (n=16), the trials with patented products (n=24) are primarily investigating the therapeutic efficacy (n=18) in patients ranging from asymptomatic to moderate to severe COVID-19 patients (Table I).

Classical interventions

**Guduchi:** *Tinospora cordifolia,* commonly named as *Guduchi,* is used in a variety of conditions in the traditional Ayurvedic literature. Guduchi has been reported to possess a range of activities (antipyretic, anti-inflammatory, antioxidant, anti-infective, anti-neoplastic and immuno-modulatory effects) notable in the context of COVID-19. Currently, in the CTRI, there are seven registered trials investigating the role of only Guduchi, in healthy high risk individuals in the community to test its role as a preventive agent against COVID-19. Four of these are large trials with sample size ranging from 5000 to 40,000 (the latter has 20 sites across India). In addition, there are three trials exploring the effects of Guduchi in combination with other agents. One of these is being conducted on 50,000 police personnel in Delhi.

**Ashwagandha:** *Withania somnifera* (Ashwagandha) is well known for its anti-inflammatory, antitumour, anti-stress, antioxidant, immunomodulatory, hemopoietic and rejuvenating properties. In addition, it has been demonstrated to inhibit certain RNA viruses. The role of Ashwagandha in the prevention of COVID-19 is being investigated in three trials registered in the CTRI, one of which is on 5000 high-risk participants.

**Turmeric:** The antiviral effects of curcumin, a plant derivative of turmeric, have been demonstrated in *in vitro* studies, which makes it an antiviral drug candidate. Evaluation of the effects of curcumin and adjuvants in COVID-19 patients, in terms of changes in acute-phase reactants and clinical outcome, is being evaluated in a randomized, parallel-group trial on 50 patients. In addition, polyherbal compounds are being investigated for immunomodulatory and antiviral properties and their potential as therapeutic and prophylactic agents.

**Patented products**

Currently, there are 24 trials registered on patented products including AYUSH-64 patented by Central Council for Research in Ayurvedic Sciences.

AYUSH 64: A multiplant formulation, AYUSH-64, has been demonstrated to be useful in several research studies carried out over several decades to treat febrile infections including malaria and is considered to possess anti-inflammatory and immunomodulatory effects. One of its components, *Glycyrrhiza glabra* or *Yashtimadhu,* has demonstrated potential as a wound-healing, anti-ulcer and anti-inflammatory agent. In addition, recent studies reveal that *Yashtimadhu* may interfere with viral entry as well as replication, thereby impacting the severity of infection. Further, AYUSH-64 along with standard care has been shown to be effective in influenza-like illnesses with potential for better outcomes. While a community-based clinical study on 1200 healthy but at-risk individuals has been registered in the CTRI to evaluate the preventive role of only *Yashtimadhu,* there are five trials on the proprietary formulation, AYUSH 64.

**Chyawanprash:** This is an ancient Indian polyherbal formulation prepared according to a traditional Ayurvedic recipe. It consists of about 50 different medicinal herbs including *Emblica officinalis* (Indian gooseberry or *Amla*), a rich source of vitamin C, as well as processed minerals and is considered as an essential health supplement. Currently, four trials are registered which are investigating the preventive role of Chyawanprash in high risk healthcare workers/containment zone population as well as the community.

**Yoga and naturopathy**

Stress is known to suppress the immune system and is believed to be the harbinger of many diseases including respiratory infections. Evidence supports the role of meditation in regulating the stress response and impacting virus-specific immune response. Further, *Pranayama* has been shown to have a positive impact on lung function. Currently, three yoga trials are registered, of which two randomized, parallel-group trials focus on the role of *Pranayama* and meditation in the prevention as well as treatment of COVID-19. In addition, in one trial, yoga is being tried in combination with naturopathy and Ayurvedic agents.

**Unani**

The Unani system of medicine, originally from Greece, has been influenced by Ayurveda, Siddha and Chinese systems of medicine. Even though an ancient system, Unani medicine also recommends isolation and quarantine during an epidemic. In addition, it also
recommends (i) cleanliness, (ii) health boosting and immune-modulation, and (iii) use of drugs. Two trials investigating the prophylactic role of Unani medicine: one is on 4000 participants and the other on 40,000 participants, have been registered in population at risk of contracting COVID-19 (Table III).

**Siddha**

The Siddha system, one of the six accepted branches of Indian systems of medicine, is particularly popular in southern India. Although it is similar to Ayurveda in certain aspects, these are two distinct streams of medicine. There are three Siddha trials registered investigating the role of *Kabasura Kudineer*, a Siddha formulation alone and in combination as a preventive agent in the management of asymptomatic COVID-19 patients (Table III).

**Homeopathy**

Homeopathy focuses on patient characteristics rather than disease per se. There has been a call to utilize the benefits of homeopathy as a therapeutic system suitable to cope with this pandemic. Several homeopathic agents have been recommended by the Ministry of AYUSH, Government of India, for the prevention of COVID-19. Of the 14 homeopathic trials registered in the CTRI, most (n=11) are of *Arsenicum album 30* or *Bryonia alba* (Table III).

**Miscellaneous trials**

Thirteen trials have been categorized as miscellaneous trials as these explore a range of interventions such as nutraceuticals, process-of-care changes (n=9) and critical care-related trials and include management of non-COVID-19 patients in the pandemic (Table I). Some of these trials evaluate methods to minimize infection risks, whereas others compare different types of video laryngoscopes for ease of intubation while wearing personal protective equipment (Table IV). Some of the other registered trials in this category include efficacy of nutraceuticals, feasibility of developing a novel artificial intelligence algorithm to screen COVID-19, telemedicine and ventilatory management training to ramp up capacity.

**Observational studies**

Apart from the clinical trials, the CTRI has registered observational studies on COVID-19 as well. Due to the imposition of lockdown and the imperative need for social distancing, observational studies have been undertaken to assess the impact of COVID-19 on mental health, clinical practice in general and in particular for oncology patients. Findings and observations from these studies would likely help develop better guidelines for the care of the most vulnerable in these pandemic times.

**Concluding remarks**

Notwithstanding the deadly virulence of the SARS-CoV-2 and the enforcement of widespread physical restrictions, medical researchers in India have risen to the dual challenge of caring for the sick and testing potential therapeutic options. This article culls the data of 122 COVID-19-related trials from the data of over 27,000 trials registered in the CTRI and presents a concise and comprehensive overview of the pharmacological and clinical aspects of the registered trials. This also provides a comprehensive insight into the COVID-19 clinical research underway in the country through CTRI database. This would encourage researchers to critically review CTRI data, identify gaps particularly methodological and design aspects of research and further decide on acceptability of the results. We hope that this information would help researchers to not only understand the clinical research scenario, but also encourage healthy debate, train researchers to avoid obvious errors/oversights, steer clear of repetitive research and indirectly promote the quality of research in the country.

**Acknowledgment:** The CTRI was set up with financial support from the ICMR, Ministry of Health and Family Welfare; Department of Science and Technology, Government of India; and World Health Organization, India Office, New Delhi, India. The CTRI website is hosted by the National Informatics Centre Services Inc., New Delhi, India. Authors acknowledge the support provided by the following: Servshti Anoop Upadhyay, Harish Kumar, and Din Bandhu, and Ms Noori Dua and Ms Deepty Rathi in the initial screening of the trials and typographical work.

**Conflicts of Interest:** None.

**Financial support & sponsorship:** None.

**References**

1. Worldometers. COVID-19 coronavirus pandemic. Available from: https://www.worldometers.info/coronavirus/, accessed on October 6, 2020.
2. COVID-19 treatment guidelines. Available from: https://covid19treatmentguidelines.nih.gov/introduction/, accessed on June 11, 2020.
3. Clinical Trials Registry - India. Available from: http://www.ctri.nic.in/Clinicaltrials/login.php, accessed on June 11, 2020.
4. World Health Organization. International Clinical Trials Registry Platform (ICTRP). Available from: https://www.who.int/ictrp/en, accessed on June 11, 2020.

5. World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments, accessed on June 11, 2020.

6. Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother 2018; 26 : 1-19.

7. Pastick KA, Okafor EC, Wang F, Logfren SM, Skipper CP, Nicol MR, et al. Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020; 7 : ofaa130.

8. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 56 : 105949.

9. Advisory on the use of hydroxychloroquine as prophylaxis for SARS-CoV-2 infection; 2020. Available from: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARS-CoV2Infection.pdf, accessed on June 11, 2020.

10. Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract 2014; 2014 : 357027.

11. Sisk JM, Frieman MB, Machamer CE. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J Gen Virol 2018; 99 : 619-30.

12. Cheriah SS, Agrawal M, Basu A, Abraham P, Gangakhedkar RR, Bhargava B. Perspectives for repurposing drugs for the coronavirus disease 2019. Indian J Med Res 2020; 151 : 160-71.

13. Singh V. Clinical outcome of a novel anti-CD6 biologic itolizumab in patients of psoriasis with comorbid conditions. Dermatol Res Pract 2016; 2016 : 1316326.

14. Krupashankar DS, Dogra S, Kura M, Saraswat A, Budamakuntla L, Sumathy TK, et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol 2014; 71 : 484-92.

15. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020; 55 : 105954.

16. Chahar M, Rawat KD, Reddy PVJ, Gupta UD, Natarajan M, Chauhan DS, et al. Potential of adjunctive Mycobacterium w (MIP) immunotherapy in reducing the duration of standard chemotherapy against tuberculosis. Indian J Tuberc 2018; 65 : 335-44.

17. Sehgal IS, Bhalia A, Puri GD, Yaddanapudi LN, Singh M, Malhotra P, et al. Safety of an immunomodulator Mycobacterium w in COVID-19. Lung India 2020; 37 : 279-1.

18. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020; 250 : 117583.

19. Moradkhani F, Moloudizargari M, Fallah M, Asghari N, Heidari Khoei H, et al. Immunoregulatory role of melatonin in cancer. J Cell Physiol 2020; 235 : 745-57.

20. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178 : 104787.

21. Xu J, Shi PY, Li H, Zhou J. Broad spectrum antiviral agent niclosamide and its therapeutic potential. ACS Infect Dis 2020; 6 : 909-15.

22. Guthappa R. Molecular docking studies of N-acetyl cysteine, zinc acetyl cysteine and niclosamide on SARS-CoV-2 protease and its comparison with hydroxychloroquine. ChemRxiv 2020. doi: 10.26434/chemrxiv.12161493.v1.

23. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 : 271-80.e8.

24. Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res 2020; 43 : 648-54.

25. Mittra I, Samant U, Sharma S, Raghuram GV, Saha T, Bidke P, et al. Cell-free chromatin from dying cancer cells integrates into genomes of bystander healthy cells to induce DNA damage and inflammation. Cell Death Discov 2017; 3 : 17015.

26. Mittra I, Pal K, Pancholi N, Bidke P, Siddiqui S, Rane B, et al. Cell-free chromatin particles released from dying host cells are global instigators of endotoxin sepsis in mice. PLoS One 2020; 15 : e0229017.

27. Ferruzzi MG, Failla ML, Schwartz SJ. Sodium copper chlorophyllin: in vitro digestive stability and accumulation by Caco-2 human intestinal cells. J Agric Food Chem 2002; 50 : 2173-9.

28. Xi H, Kurtoglu M, Lampidis TJ. The wonders of 2-deoxy-D-glucose. IUBMB Life 2014; 66 : 110-21.

29. Balkrishna A, Thakur P, Singh S, Dev S, Jain V, Varshney A, et al. Glucose antimetabolite 2-Deoxy-D-Glucose and its derivative as promising candidates for tackling COVID-19: Insights derived from in silico docking and molecular simulations. Authorea 2020. doi: 10.22541/au.158567174.40895611.

30. Balkrishna A, Pokhrel S, Singh J, Varshney A. Withanone from Withania somnifera may inhibit novel coronavirus (COVID-19) entry by disrupting interactions between viral s-protein receptor binding domain and host ACE2 receptor; 2020. doi: 10.21203/rs.3.rs-17806/v1.

31. Meena MK, Singh N, Meena R, Patni V. Quantitative determination of gallic acid from methanolic extract of Cocculus hirsutus using HTPLC. Int J Pharm Bio Arch 2016; 7 : 6-10.
32. Khader M, Eckl PM. Thymoquinone: an emerging natural drug with a wide range of medical applications. Iran J Basic Med Sci 2014; 17: 950-7.
33. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liambruno GM, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016; 14: 152-7.
34. World Health Organization. WHO Blood Regulators Network (BRN): Position paper on collection and use of convalescent plasma or serum as an element in Filovirus outbreak response. Available from: https://www.who.int/bloodproducts/brn/BRN_PositionPaperConvPlasmaFiloviruses_FINALWEB14August2014.pdf?ua=1, accessed on June 11, 2020.
35. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol 2020; 10.1002/jmv.25961.
36. Yang L, Tian D, Liu W. Strategies for vaccine development of COVID-19. Sheng Wu Gong Cheng Xue Bao 2020; 36: 593-604.
37. Tanner R, Villarreal-Ramos B, Vordermeier HM, McShane H. The humoral immune response to BCG vaccination. Front Immunol 2019; 10: 1317.
38. Neelakantan V. Tuberculosis control in postcolonial South India and beyond: Fractured sovereignties in international health, 1948-1960. Wellcome Open Res 2017; 2: 4.
39. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv 2020. doi: 10.1101/2020.03.24.20042937.
40. Advisory from Ministry of AYUSH for meeting the challenge arising out of spread of coronavirus (COVID-19) in India. Available from: https://www.ayush.gov.in/docs/125.pdf, accessed on June 11, 2020.
41. Mishra L, Singh BB, Dagenais S. Ayurveda: a historical perspective and principles of the traditional healthcare system in India. Altern Ther Health Med 2001; 7: 36-42.
42. Saha S, Ghosh S. Tinospora cordifolia: One plant, many roles. Anc Sci Life 2012; 31: 151-9.
43. Upadhyay AK, Kumar K, Kumar A, Mishra HS. Tinospora cordifolia (Willd.) Hook. f. and Thoms. (Guduchi) - validation of the Ayurvedic pharmacology through experimental and clinical studies. Int J Ayurveda Res 2010; 1: 112-21.
44. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): A review. Altern Med Rev 2000; 5: 334-46.
45. Ganguly B, Umapathi V, Rastogi SK. Nitric oxide induced by Indian ginseng root extract inhibits infectious Bursal Disease virus in chicken embryo fibroblasts in vitro. J Anim Sci Technol 2018; 60: 2.
46. Moghadamtousi SZ, Kadir HA, Hassandanrash P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int 2014; 2014: 186864.
47. AYUSH-64. An ayurvedic antimalarial drug. Available from: http://www.eccrus.nic.in/sites/default/files/viewpdf/IEC_Communication/Ayush%2064.pdf, accessed on June 11, 2020.
48. Das D, Agarwal SK, Chandola HM. Protective effect of Yashtimadhu (Glycyrrhiza glabra) against side effects of radiation/chemotherapy in head and neck malignancies. Ayu 2011; 32: 196-9.
49. Maurya DK. Evaluation of Yashtimadhu (Glycyrrhiza glabra) active phytochemicals against novel coronavirus (SARS-CoV-2). Research Square 2020. doi.org/10.21203/rs.3.rs-26480/v1.
50. Gundeti MS, Bhurke LW, Mundada PS, Murudkar S, Surve A, Sharma R, et al. AYUSH 64, a polyherbal Ayurvedic formulation in Influenza like Illness: Results of a pilot study. J Ayurveda Integr Med 2020. doi:10.1016/j.jaim.2020.05.010.
51. Sharma R, Martins N, Kuca K, Chaudhary A, Kabra A, Rao MM, et al. Chyawanprash: A traditional Indian bioactive health supplement. Biomolecules 2019; 9: 161.
52. Salleh MR. Life event, stress and illness. Malays J Med Sci 2008; 15: 9-18.
53. Maxwell L, Barrett B, Chase J, Brown R, Ewers T. Self-reported mental health predicts acute respiratory infection. WMJ 2015; 114: 100-4.
54. Househam AM, Peterson CT, Mills P, Chopra D. The effects of stress and meditation on the immune system, human microbiota, and epigenetics. Adv Mind Body Med 2017; 31: 10-25.
55. Morgan N, Irwin MR, Chung M, Wang C. The effects of mind-body therapies on the immune system: Meta-analysis. PLoS One 2014; 9: e100903.
56. Budhi RB, Payghan S, Deepeshwar S. Changes in lung function measures following Bhastrika Pranayama (Bellows Breath) and running in healthy individuals. Int J Yoga 2019; 12: 233-9.
57. Nikhat S, Fazil M. Overview of Covid-19; its prevention and management in the light of Unani medicine. Sci Total Environ 2020; 728: 138859.
58. Muthiah K, Ganesan K, Ponnaiah M, Parameswaran S. Concepts of body constitution in traditional Siddha texts: A literature review. J Ayurveda Integr Med 2019; 10 : 131-4.
59. Poitevin B. Integrating homeopathy in health systems. Bull World Health Organ 1999; 77: 160-6.
60. Kalliantas D, Kallianta M, Karagianni CS. Homeopathy for prevention of coronaviruses infections. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1600895, accessed on June 11, 2020.

For correspondence: Dr Mohua Maulik, Clinical Trial Registry - India, ICMR-National Institute of Medical Statistics, New Delhi 110 029, India e-mail: mohua.maulik@gmail.com